Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Cardiac function in hereditary transthyretin amyloidosis
Document related concepts
Electrocardiography wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Coronary artery disease wikipedia , lookup
Echocardiography wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Transcript
Cardiac function in hereditary transthyretin amyloidosis - An echocardiographic study Sandra Arvidsson Department of Public Health and Clinical Medicine Umeå University, Umeå 2016 Responsible publisher under Swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7601-399-1 ISSN: 0346-6612 New Series No. 1774 Cover by: Print & Media Elektronisk version tillgänglig på http://umu.diva-portal.org/ Tryck/Printed by: Print & Media, Umeå University Umeå, Sweden, 2016 Success is not final, failure is not fatal It is the courage to continue that counts W. Churchill Innehåll/Table of Contents Innehåll/Table of Contents i Abstract iii Original articles v Abbreviations vi Sammanfattning på svenska viii Ärftlig transtyretin-amyloidos viii Amyloidinlagring i hjärtat ix Introduction 1 Amyloidoses 1 Transthyretin and misfolding 2 Hereditary transthyretin amyloidosis 2 Disease manifestations 3 V30M 3 Wild type transthyretin amyloidosis 4 Fibril composition 4 Phenotypic heterogeneity 4 Treatment 6 Cardiac amyloidosis 7 Ventricular involvement and function 7 Definition of cardiac amyloidosis 8 Role of echocardiography in identifying cardiac amyloidosis 9 Echocardiographic characteristics 9 Novel echocardiographic methods 10 Electrocardiography 12 Other imaging modalities 12 Differential diagnoses 13 Sarcomeric hypertrophic cardiomyopathy 13 Storage diseases 14 Objectives 15 Materials and methods 16 Study population 16 Methodology 18 Echocardiography 18 Two dimensional and M-mode echocardiography 19 Doppler echocardiography 19 Deformation analysis 19 Myocardial tissue characterisation 21 Electrocardiography 22 Statistics 22 Classification trees 22 i Reproducibility 23 Ethics 23 Results and Discussion 24 Differentiating ATTR amyloidosis from HCM 24 Classification tree 27 Right heart involvement in ATTR amyloidosis 29 Cardiac involvement according to fibril composition 29 Dispersion of fibril composition among V30M patients 30 Determinants of increased LV wall thickness 31 Sex-related differences in cardiac involvement 32 Fibril composition determines outcome after liver transplantation 35 Liver transplantation as a treatment option 36 Methodological considerations 37 Limitations 38 Conclusions 39 Acknowledgements 40 References 42 ii Abstract Background: Hereditary transthyretin amyloidosis (ATTR) is a lethal disease in which misfolded transthyretin (TTR) proteins accumulate as insoluble aggregates in tissues throughout the body. A common mutation is the exchange of valine to methionine at place 30 (TTR V30M), a form endemically found in the northern parts of Sweden. The main treatment option for ATTR amyloidosis is liver transplantation as the procedure halts production of mutated transthyretin. The disease is associated with marked phenotypic diversity ranging from predominant cardiac complications to pure neuropathy. Two different types of fibril composition – one in which both fragmented and full-length TTR are present (type A) and one consisting of only full-length TTR (type B) have been suggested to account for some phenotypic differences. Cardiac amyloidosis is associated with increased myocardial thickness and the disease could easily be mistaken for other entities characterised by myocardial thickening, such as sarcomeric hypertrophic cardiomyopathy (HCM). The aims in this thesis were to investigate echocardiographic characteristics in Swedish ATTR amyloidosis patients, and to identify markers aiding in differentiating ATTR heart disease from HCM. Another objective was to examine the impact of fibril composition and sex on the phenotypic variation in amyloid heart disease. Methods: A total of 122 ATTR amyloidosis patients that had undergone thorough echocardiographic examinations were included in the studies. Analyses of ventricular geometry as well as assessment of systolic and diastolic function were performed, using both conventional echocardiographic methods and speckle tracking technique. ECG analysis was conducted in study I, allowing measurement of QRS voltage. In study I and study II ATTR patients were compared to patients with HCM. In addition, 30 healthy controls were added to study II. Results: When parameters from ECG and echocardiography were investigated, the results revealed that the combination of QRS voltage <30 mm (<3 mV) and an interventricular/posterior wall thickness quotient <1.6 could differentiate cardiac ATTR amyloidosis from HCM. Differences in degree of right ventricular involvement were also demonstrated between HCM and ATTR amyloidosis, where ATTR patients displayed a right ventricular apical sparing pattern whereas the inverse pattern was found in HCM. Analysis of fibril composition revealed increased LV wall thickness in type A patients compared to type B, but in addition type A women displayed both lower myocardial thickness and more preserved systolic function as compared to type A males. When cardiac geometry and function were iii evaluated pre and post liver transplantation in type A and B patients, significant deterioration was detected in type A but not in type B patients after liver transplantation. Conclusions: Increasing awareness of typical cardiac amyloidotic signs by echocardiography is important to reduce the risk of delayed diagnosis. Our classification model based on ECG and echocardiography could aid in differentiating ATTR amyloidosis from HCM. Furthermore, the apical sparing pattern found in the right ventricle may pose another clue for amyloid heart disease, although it requires to be studied further. Furthermore, we disclosed that type A fibrils, male sex and increasing age were important determinants of increased myocardial thickness. As type A fibril patients displayed rapid cardiac deterioration after liver transplantation other treatment options should probably be sought for this group of patients. iv Original articles This study is based on the following articles, referred by the corresponding Roman numerals in the text. I. Gustavsson S, Granåsen G, Grönlund C, Wiklund U, Mörner S, Henein M, Suhr OB, Lindqvist P. Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy? Amyloid. 2015;22(3):163-70. II. Arvidsson S*, Henein M, Wikström G, Suhr OB, Lindqvist P. Right ventricular involvement in transthyretin amyloidosis. Manuscript. III. Arvidsson S*, Pilebro B, Westermark U, Lindqvist P, Suhr OB. Amyloid cardiomyopathy in hereditary transthyretin Val30Met amyloidosis impact of sex and amyloid fibril composition. PLoS One. 2015;10(11):e0143456. doi: 10.1371/journal.pone.0143456. IV. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation. 2012;93(10):1017-23. All articles and figures in the thesis are reproduced by kind permission from the publishers. * Gustavsson was changed to Arvidsson in 2015. v Abbreviations 2D 99mTc-DPD AA AL AoVmax ASE ATTR ATTRm ATTRwt AUC BSA CI CO DICOM DT E/A ECG EDVI e’ or Em ESVI FAP GSM HCM HFpEF HREs IVRT IVST LA LAVI ln LT LV LVDD LVEF LVMI LVMI LVSD MRI PET PWT Two-dimensional 99mTc-3.3-diphosphono-1.2-propanodicarboxylic acid Amyloid A Amyloid Light Chain Peak Systolic Aortic Flow Velocities American Society of Echocardiography Transthyretin Amyloid Transthyretin Amyloid mutated Transthyretin Amyloid wild type Area Under the Curve Body Surface Area Cardiac Index Cardiac Output Digital Imaging and Communications in Medicine Deceleration time Early to Late Ventricular Filling Velocities Ratio Electrocardiography End-diastolic Volume Index Early Diastolic Tissue Doppler Velocities End-systolic Volume Index Familial Amyloidosis with Polyneuropathy Gray-Scale Median Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction Highly Reflective Echoes Isovolumic Relaxation Time Interventricular Septal Thickness Left Atrial Left Atrial Volume Index Natural Logarithm Liver Transplantation Left Ventricle Left Ventricular Diastolic Dimension Left Ventricular Ejection Fraction Left Ventricular Mass Index Left Ventricular Mass Index Left Ventricular Systolic Dimension Magnetic Resonance Imaging Positron Emission Tomography Posterior Wall Thickness vi ROC RV RVT SAM SI SV TAPSE TTR Type A Type B Receiver-Operating Characteristics Right ventricle Right Ventricular Thickness Systolic Anterior Motion Stroke Index Stroke Volume Tricuspid Longitudinal Systolic Displacement Transthyretin Full-length + Fragments of Transthyretin Proteins Full-length Proteins only vii Sammanfattning på svenska Ärftlig transtyretin-amyloidos Amyloidos är ett samlingsnamn för en rad sjukdomar som har gemensamt att missbildade proteiner klumpas samman och lagras in i organ och vävnader i kroppen. Alzheimers och Parkinsons sjukdom tillhör några av de vanligare amyloid-relaterade sjukdomarna. Sjukdomen ärftlig transtyretin amyloidos (ATTR-amyloidos), i dagligt tal mer känd som Skellefteåsjukan är en annan variant, där proteinet transtyretin ligger bakom amyloidinlagringen. Transtyretin tillverkas främst i levern och fungerar som ett transportprotein som cirkulerar i blodet. ATTR-amyloidos är ovanligt förekommande i större delen av världen men i regioner i Portugal, Japan och i Norr- och Västerbotten i Sverige förekommer sjukdomen i betydligt högre utsträckning. I den svenska befolkningen beräknas nästan 2% bära på den sjukdomsorsakande genförändringen men långt ifrån alla genbärare utvecklar sjukdomen. ATTR-amyloidos visar sig vanligen i form av nervpåverkan med smärta och nedsatt känsel i fötter, ben och så småningom övre extremiteter. Även besvär från mag-tarmkanalen är vanliga liksom hjärtbesvär. När amyloidinlagringen drabbar hjärtat ses vanligen en förtjockad hjärtmuskel, påverkan på hjärtrytmen och vid sena skeden av sjukdomen uppstår hjärtsviktssymtom. Sedan drygt 20 år tillbaka har levertransplantation varit den enda fungerande behandlingen för ATTR-amyloidos, detta då produktionen av missbildat transtyretin upphör när den sjuka levern ersätts med en frisk, vilket också stannar av sjukdomsprocessen. Tyvärr fortsätter sjukdomen utvecklas hos somliga patienter, främst i form av fortsatt amyloidinlagring i hjärtat. På senare tid har andra behandlingsformer tagits fram där de mest lovande fokuserar på att minska amyloidbildningen genom att stabilisera transtyretinproteinet och tysta den gen som bildar transtyretin. Symtomen hos patienter med ATTR-amyloidos varierar kraftigt, vanligen uppvisar patienter blandade symtom men hos vissa patienter sker amyloidinlagringen nästan enbart i hjärtmuskeln medan den hos andra främst drabbar nervsystemet. Dessa variationer har noterats mellan olika geografiska sjukdomsområden, mellan olika mutationer men förvånande nog även inom samma genförändring och inom enskilda familjer. Hos svenska familjer med ATTR-amyloidos har det noterats att yngre patienter ofta drabbas av symtom främst från nervsystemet medan äldre patienter snarare uppvisar hjärtsymtom. Även skillnader mellan könen har noterats, där män i högre utsträckning än kvinnor verkar drabbas av hjärtengagemang. Det finns många oklarheter i varför en så varierande viii symtombild finns men också varför vissa patienter drabbas av hjärtkomplikationer efter levertransplantation medan sjukdomen avstannar hos andra. Studier har visat att proteinsammansättningen vid ATTR-amyloidos kan förekomma i två former, i den ena varianten lagras både intakta och fragment av proteiner in i vävnader (fibrilltyp A) och i den andra formen består inlagringen endast av intakta proteiner (fibrilltyp B). Dessa två typer av inlagring har presenterats som en möjlig förklaring till de varierande symtomen. Mindre studier har visat att patienter med typ A-fibriller oftare har hjärtsymtom medan typ B i större utsträckning är associerat med nervpåverkan. Amyloidinlagring i hjärtat När ATTR-amyloidos drabbar hjärtat uppstår främst en ökad förtjockning av hjärtmuskeln, något som leder till gradvis försämrad fyllnads- och pumpförmåga. Till en början ger hjärtinlagringen inga uppenbara symtom men så småningom brukar andfåddhet-, ansträngningsintolerans och trötthetssymtom uppstå. I vissa fall, när amyloidinlagringen nästan uteslutande drabbar hjärtmuskeln kan symtomen vara ganska ospecifika vilket försvårar diagnostiken. Graden av inlagring och påverkan utreds vanligen via en ultraljudsundersökning av hjärtat. Denna undersökning ger en bred information om storlek på både vänster- och högersidiga hjärtrum, tjocklek på hjärtmuskeln, utseende och funktion av klaffar och även pumpförmåga, bland annat genom beräkning av slag- och hjärtminutvolym. Ofta utförs också en elektrokardiografisk (EKG) undersökning som främst ger information om hjärtrytmen men som också kan registrera tecken på förtjockad hjärtmuskel, ofta i form av höga amplituder på EKG-kurvan. En förtjockad hjärtmuskel är ett relativt vanligt fynd vid en ultraljudsundersökning och beror oftast på en historik av högt blodtryck. Hypertrof kardiomyopati (HCM) är ett annat exempel på en hjärtsjukdom som karakteriseras av ökad hjärtmuskeltjocklek. Den hjärtmuskelförtjockning som ses vid ATTR-amyloidos är svår att särskilja från andra orsaker till förtjockat hjärta och detta medför att ATTR-amyloidos felaktigt kan misstas för någon av ovan beskriva tillstånd och därmed finns risk att patienter erhåller fel behandling för sin sjukdom. Det är därför av stor vikt att hitta specifika tecken på att just amyloidos drabbat hjärtat. Sammanfattning av fynd i denna avhandling I arbete I och II undersökte vi hjärtat med en rad olika ultraljudsmått hos patienter med ATTR amyloidos, i syfte att finna parametrar som är specifika för just den sjukdomen. Som jämförelse testade vi även dessa ultraljudsmått på patienter med HCM. Arbete I visade att hos patienter där ATTRamyloidos drabbat hjärtat ses en dämpning av den elektriska signal som ix registreras på ett EKG i motsats till patienter med HCM, där vanligen förhöjda amplituder sågs. Utöver detta fann vi att vägg-förtjockningen var mer jämnt fördelad i vänster kammare hos ATTR-patienter medan HCMpatienter uppvisade betydligt tjockare kammar-skiljevägg än övriga segment. När dessa två fynd kombinerades separerades ATTR-amyloidos från HCMpatienter i hög utsträckning. Arbete II fokuserade på den högra hjärthalvan där målet också var att kartlägga i vilken utsträckning amyloidinlagringen drabbar höger kammare. Vi såg att ökad väggtjocklek i höger kammare är relativt vanligt hos patienter med ATTR-amyloidos, men endast hos patienter som hade samtidig förtjockning av vänster hjärtmuskel. Utöver detta fann vi ett rörelsemönster i höger kammares vägg som inte liknande det som sågs hos HCM-patienter, där amyloidos-patienter hade mest bevarad funktion i hjärtspetsen medan HCM patienter tvärtom hade mest nedsatt funktion i motsvarande delar. Dessa två studier visar på skillnader i ultraljuds- och EKG-fynd mellan två bakomliggande orsaker till förtjockad hjärtmuskel (ATTR-amyloidos och HCM), vilket kan bidra till lättare identifiering av ATTR-amyloidos och därmed minska risken för feldiagnostisering. I arbete III och IV utredde vi betydelsen av de två typerna av proteinssammansättning för utveckling av hjärtengagemang och i arbete III analyserades också skillnader mellan könen hos svenska patienter med ATTR-amyloidos. Arbete III visade att patienter med fibrilltyp A hade en klart ökad förekomst av hjärtengagemang jämfört med patienter med typ B. Det fanns också en könsskillnad, där män med fibrilltyp A uppvisade tecken på gravare amyloidinlagring i hjärtat jämfört med kvinnor. Detta sågs både genom ökad hjärtmuskeltjocklek hos män men också mer nedsatt pumpfunktion. Arbete IV jämförde graden av hjärtpåverkan före och efter levertransplantation. Detta arbete påvisade en ökad väggtjocklek och försämrad hjärtfunktion hos samtliga patienter med typ A-fibriller medan patienter med typ B klarade sig betydligt bättre. Sammanfattningsvis visar dessa två arbeten att fibrilltyp och kön har en avgörande roll för sjukdomsbilden hos patienter med ATTR-amyloidos och att levertransplantation sannolikt inte är en lämplig behandling hos patienter med typ A-varianten. x xi Introduction Amyloidoses Amyloidoses are a group of diseases characterised by extracellular deposition of structurally altered proteins in organs and tissues. The diseases are classified by the nature of the precursor protein that forms the amyloid fibrils and at present, at least 30 different precursor proteins could give rise to amyloidotic diseases. Amyloid diseases occur systemically or localized to one organ or tissue and are either inherited or acquired. Amyloid has certain characteristics collective for all precursor proteins, such as being insoluble and having a fibrillar ultrastructure which after staining with Congo red shows a birefringence in polarized light [1-3] (figure 1). The most prevalent amyloidotic disease is medin-amyloidosis, present in the walls of the thoracic arteries in most individuals above the age of 50 [4]. Among diseases characterised by local deposition of amyloid, Alzheimer’s disease is probably the most well-known. Prion diseases such as CreutzfeldtJacob are also characterised by local amyloid-like deposits. Amyloid Light Chain amyloidosis (AL), caused by plasma cell dyscrasia is an acquired disease existing in both local and systemic forms. The systemic form of AL amyloidosis affects any part of the body except the brain, and frequently involves the kidneys and the heart [2]. In hereditary systemic amyloidoses, genetically variant precursor proteins are responsible for amyloid formation, most commonly caused by a mutation in the gene for the protein transthyretin. Apolipoproteins AI and AII, fibrinogen A α-chain, gelsolin, Cystatin C and lysozyme are other proteins responsible for hereditary amyloidosis [5]. Systemic amyloidosis can also occur secondary to long-standing chronic infections and inflammatory diseases such as Crohn’s disease and rheumatoid arthritis and is then termed Amyloid A (AA) amyloidosis [6]. Figure 1. Congo red staining of myocardial tissue from a patient with amyloid cardiomyopathy. A, Light microscopy; B, polarized light microscopy, 400× magnification. From Ruberg et al. review published in Circulation. 2012;126:12861300. 1 Transthyretin and misfolding Transthyretin (TTR) is a plasma protein that serves as a transport molecule for thyroxine and indirectly for retinol. TTR is a tetrameric protein, consisting of four identical sub-units where each sub-unit is constituted of 127 amino acid residues. The protein is mainly synthesized in the liver, although small amounts are also produced in the choroid plexus, the retinal pigment epithelium of the eye, and in alpha cells in the pancreatic islets of Langerhans [7-10]. Variant TTR is circulating from birth in patients carrying the genetic mutation but it is not completely clarified what factors trigger initiation of amyloid formation and disease onset. However, it is generally accepted that most TTR mutations render the tetramer unstable and more prone to dissociate into structurally altered monomers with high propensity to enter a misfolded state. Misfolded monomers are susceptible to self-aggregation and constitute the base for the cross B structure known as amyloid fibrils [11] (figure 2). Intriguingly, wild type tetramers also hold the ability to disassemble and become amyloidogenic in elderly indicating that ageing has an important role in amyloid formation [12, 13]. Native tetramer Folded monomers Misfolded monomers Oligomer Amyloid fibril Figure 2. Schematic illustration of transthyretin misfolding and amyloid fibril formation. Hereditary transthyretin amyloidosis Hereditary transthyretin amyloidosis (ATTR) is a globally rare but lethal disease which, until recently, has been denominated as familial amyloidotic polyneuropathy (FAP) since sensorimotor neuropathy is a predominant feature in many of the TTR mutations. Some initial descriptions of the amyloidotic disease were presented in 1938 when De Navasques and Treble performed autopsy studies on patients with polyneuropathy and reported the presence of amyloid in the nervous system [14]. A familial form of the disease was originally described in the Portuguese population by Andrade [15]. Later, another large foci was detected in Japan [16] and Andersson described a large number of families with FAP in Sweden in 1976 [17]. ATTR amyloidosis is inherited in an autosomal dominant fashion, and to date more 2 than 100 TTR mutations have been described, of which the vast majority are amyloidogenic [7, 18]. Disease manifestations Early manifestations of the disease are usually related to small sensory fibre dysfunction resulting in pain, sensory loss and impaired ability to recognise thermal changes [19]. Along with disease progression, motor neuropathy becomes more prominent, advancing proximally from feet to ankles, knees and upper extremities. Other frequent symptoms are gastro-intestinal dysfunction including vomiting, diarrhea or constipation as a result of autonomic neuropathy [20]. Sexual impotence, bladder retention and reduced blood pressure control are also frequently encountered autonomic symptoms [17]. Amyloid deposition in the heart, preferentially the cardiac walls, is a well described manifestation of the ATTR disease resulting in conduction disturbances and arrhythmia often leading to pacemaker treatment [21], but also progressive heart failure with symptoms of dyspnoea and exercise intolerance [22, 23]. Less common symptoms of ATTR amyloidosis are proteinuria and kidney dysfunction caused by amyloid deposition in the kidneys, and vitreous opacities caused by TTR synthesized in the eye [7]. In end stage disease patients are severely disabled, malnourished, in pain and are unable to take care of themselves [17]. V30M The most common mutation associated with polyneuropathy is the V30M variant where the amino-acid valine is replaced by methionine at position 30, calculated from the beginning of the protein’s coding region [17]. ATTR V30M is endemically found in regions in northern Portugal, Brazil, in two geographic areas in Japan, and in the counties of Norrbotten and Västerbotten in the northern parts of Sweden [17, 24, 25]. However, the disease mutation is not restricted to endemic areas but is also found worldwide. The carrier frequency of the disease mutation is estimated to 1.95 % in the Swedish cluster [26]. Mutation carriers that develop ATTR amyloidosis have a bleak prognosis if the disease remains untreated, with a mean survival of thirteen years after onset of disease [27]. Despite sharing the same genotype, a substantial heterogeneity of penetrance, and age of onset are expressed between the different endemic areas. In the Portuguese mutation carriers, penetrance is 80% around 50 years of age in contrast to the Swedish cluster where penetrance for a similar age is markedly lower, estimated at 11%. Traditionally, ATTR V30M patients are described as having either early-onset (<50 years of age) or late-onset (>50 years) of symptomatic disease [22, 28, 29]. Both the Japanese and Portuguese clusters generally have early-onset of symptoms with 33 years in 3 mean age while the mean age of onset in Swedish V30M patients is higher, around 56 years [22, 30, 31]. Wild type transthyretin amyloidosis In wild type ATTR amyloidosis (ATTRwt), previously denominated senile systemic amyloidosis, the amyloid deposits are derived from normal (nonmutated) TTR [32]. ATTRwt amyloidosis predominantly affects elderly males and the amyloid fibrils have a predilection for the heart. Other sites for infiltration are the lungs and vessels, and mild sensory neuropathic manifestations have also been reported [23, 33, 34]. The ability for native TTR proteins to form amyloid in elderly is likely linked to the protein becoming more structurally unstable with increasing age, thus resulting in the misfolded intermediates that leads to protein aggregation and amyloid formation [13]. Autopsy studies have demonstrated that amyloid deposits could be detected in approximately 25% of all individuals above the age of 85, although in most cases in insignificant amounts [35, 36]. Fibril composition Fibril composition in ATTR amyloidosis is not uniform but exists in two distinct morphologic patterns - either as a mix of full-length and C-terminal TTR fragments (type A) or only as intact TTR (type B). Bergström et al. demonstrated that the amyloid deposition pattern in cardiac tissue differs between the two fibril types. Type A was associated with large, widespread amyloid deposits in the sub-endocardium, epicardium and myocardium, often replacing normal tissue architecture. In contrast, cardiac tissue with type B fibrils contained smaller clusters of amyloid, situated in the subendocardium or epicardium, frequently formed in thin threadlike structures [37]. The importance of these distinct fibril types in ATTR amyloidosis has been sparsely investigated but small studies have indicated a relation between fibril composition and disease phenotype, at least in patients with the TTR V30M mutation [38, 39]. Phenotypic heterogeneity The disease phenotype in ATTR amyloidosis is heterogeneous and could roughly be categorised as predominantly cardiac, predominantly neuropathic and mixed phenotype [40]. The vast majority of patients present with a mix of symptoms. The phenotypic differences could partially be attributed to different genotypes (figure 3), but a substantial phenotypic diversity has also been described between different geographical 4 populations, endemic and non-endemic areas and even within the same TTR mutation [22, 25, 29, 40]. Among the TTR point mutations associated with predominant cardiac phenotype the V122I is the most prevalent. ATTR V122I has a prevalence around 3-4% among African-Americans in the US population, predominantly affecting males above the age of 60. Thus, the clinical course of ATTR V122I and age of onset closely resembles the disease profile present in ATTRwt amyloidosis [23, 41, 42]. Despite the rather late mean age of onset in Swedish ATTR amyloidosis patients, a subset of patients has early-onset of disease, usually presenting initial symptoms in their twenties to forties. Early-onset ATTR V30M patients usually manifest small fibre neuropathy, gastro-intestinal disturbances and cardiac conduction abnormalities. In contrast, late onset patients have more profound motor neuropathy and cardiac dysfunction manifested as progressive development of heart failure [28, 29]. This has also been described in other V30M populations and the distinct disease manifestations go well in line with demonstrated pathological findings [23, 43]. The mechanisms behind the different phenotypes are not yet fully understood but previous studies have introduced fibril composition as one potential explanation. Type A TTR fibrils are more frequently encountered in non V30M genotypes and late-onset V30M patients, thus including the groups of patients with strongest association to cardiac involvement, ie., amyloid cardiomyopathy [38, 39, 44]. Intriguingly, type A TTR fibrils are the exclusive variant found in ATTRwt amyloidosis [37], which mainly presents as a cardiac disease in males. Furthermore, sex-related discrepancies have also been reported in some ATTR populations, where especially late-onset males seem to have a predilection for the cardiac phenotype [29, 45]. The extent of male dominance for the cardiac phenotype in different TTR mutations is not fully elucidated, and underlying mechanisms for the proposed differences are not completely understood. However, hormonal protection in women has been suggested as a potential mechanism and experimental studies in mice have demonstrated that androgens enhances TTR synthesis and increases circulating TTR levels more strongly than oestrogen [46]. 5 Figure 3. Genotype-phenotype correlations in transthyretin amyloidosis. Primarily neuropathy (left), mixed phenotypes (middle portion) and predominant cardiac phenotypes (right). Note that the V30M mutation is categorised into subgroups where early-onset patients mainly exhibit polyneuropathy whereas the cardiac phenotype dominates in late-onset patients. From Rapezzi et al. Published in European Heart Journal 2013 34, 520–528. Treatment Liver transplantation (LT) has been the only available treatment option for patients with hereditary ATTR amyloidosis. As the vast majority of TTR is synthesized in the liver, replacing the variant TTR producing liver ceases production of the amyloid precursor protein. The first LT on a patient with ATTR amyloidosis was carried out in Sweden in 1990 and to date more than 2000 transplants have been performed (http://www.fapwtr.org/ram_fap.htm). Overall, LT has showed a favourable outcome with increased survival, halted disease progression and improved quality of life. However, follow-up studies have revealed that careful patient selection is crucial for the outcome. Best outcome has been demonstrated in early-onset patients and in late-onset females. In addition, patients should have adequate nutritional status and LT should preferably be carried out shortly after onset of symptoms [47-49]. The majority of LT has been performed in ATTR V30M patients as survival is better for this genotype than for non-V30M patients [50]. Moreover, continuous deterioration after LT has been described especially in terms of cardiac function [51]. Progression of arrhythmias and rapid development of amyloid cardiomyopathy are the main complications post LT, predominantly occurring in late-onset males and in non-V30M patients [21, 52, 53] and are explained by continuous accumulation of wild type ATTR fibrils in the heart. It is not completely understood why only 6 some patients exhibit this rapid exacerbation after LT. Cardiovascular complications are a major cause of death in liver transplanted ATTR patients and have led to combined heart and liver transplant in some cases [50, 5355]. As for treatment of clinical manifestations of heart failure, many of the traditional medical therapies are contraindicated or should be used cautiously in patients with ATTR amyloidosis patients due to lack of tolerability, often as a consequence of autonomic neuropathy [56-58]. Recently, the first compound designed to slow down amyloid formation was approved for clinical use (Tafamidis). The drug’s target is to stabilize the tetramers, preventing them from dissociating into monomers and assembling into amyloid fibrils. Studies have detected that the compound successfully slowed down disease progression, especially those related to neuropathy [59]. Similar properties have been shown for a non-proprietary drug, diflunisal [60]. Longer follow-up studies are still lacking and current recommendations suggest Tafamidis treatment in early onset, predominant neuropathic ATTR disease [61]. Other pharmacologic treatments are currently undergoing clinical trials, of which silencing of the TTR gene has shown promising results by eliminating more than 80% off all circulating TTR (both mutant and wild type) in ATTR amyloidosis patients and healthy controls [62]. Cardiac amyloidosis The label cardiac amyloidosis contains a diverse set of diseases with their own phenotypical patterns and clinical courses. At present, 11 proteins are associated with cardiac amyloidosis of which AL and ATTR variants account for approximately 98% of all clinical cases, with AL amyloidosis being the most common [63]. Hence, AL, ATTR mutated variant (ATTRm) and ATTRwt will be the three main types of amyloidosis discussed in this thesis. Amyloid deposits could affect most cardiac sites and collective features for the main types of cardiac amyloidosis include thickening of the ventricular and atrial walls, as well as cardiac valves. Other sites for infiltration are small vessels and the conduction system [64-67]. Ventricular involvement and function Functionally, various degrees of left ventricular (LV) systolic and diastolic dysfunction are displayed. Longitudinal LV function is compromised early in the disease process, initiated with impairment in the basal and mid segments of the LV [65, 68, 69]. Despite this, global LV function, at least in terms of ejection fraction (LVEF) and stroke volume (SV) frequently remains preserved or only slightly impaired despite extensive amyloid deposits in the myocardium. This especially holds true for ATTRm [65, 70]. ATTR 7 amyloidosis may present as heart failure with preserved ejection fraction (HFpEF), and a recent study by González-López et al. reported a prevalence for ATTRwt of 13% among patients above the age of 60 diagnosed with HFpEF and having concomitant LV wall thickness >12 mm [71]. Early stages of amyloid cardiomyopathy are associated with altered ventricular relaxation but as the amyloid burden in the LV wall increases it renders the myocardium stiff and non-compliant. This gradually impairs LV diastolic filling and ultimately leads to an increase in left atrial filling pressure and restrictive filling [72, 73]. Restrictive LV filling is a well described hallmark for amyloid cardiomyopathy [74], however, reports on AL and ATTRm cohorts have demonstrated that far from all patients with substantial myocardial infiltration exhibit severe diastolic dysfunction [64, 75]. The prevalence and rate of development of increased diastolic filling pressures of course varies with the underlying amyloid disease, but it should generally be regarded as a common feature only in advanced amyloid cardiomyopathy [76]. In AL related amyloidosis a second mechanism is involved, namely cell toxicity, mediated by cardiac light chain proteins. This causes rapid deterioration of LV myocardial function and presence of heart failure symptoms shortly after disease onset [77, 78]. This renders AL amyloidosis the most toxic of the three disease entities, hence being the disease with shortest survival [64]. Conversely, ATTRm and ATTRwt amyloidosis are associated with slower disease progression and longer survival despite more extensive thickening of the myocardium [33, 64, 65, 79]. Right heart involvement is a relatively frequent feature of the AL variant of cardiac amyloidosis in which decreased right ventricular (RV) systolic function is associated with a poor prognosis [80, 81]. However, RV involvement and function in ATTR amyloidosis has been somewhat overlooked. Quarta et al. reported comparable thickening of the RV free wall in AL, ATTRm and ATTRwt amyloidosis patients [65]. Reduced longitudinal RV function has also been described in a few studies [70, 82]. Definition of cardiac amyloidosis The myocardium can be categorised in three different compartments. First, there is the muscular part that to a large extent is built up of myocytes. The second part is the interstitial compartment comprising fibroblasts and collagen and the third part is vascular, containing smooth muscle and endothelial cells [83]. While pressure-overload conditions will induce myocyte hypertrophy the thickening of the myocardium present in amyloid heart disease is caused by amyloid deposition in the interstitial compartment. Current guidelines categorises amyloid heart disease as both hypertrophic and as restrictive cardiomyopathies. However, the term 8 ‘hypertrophic’ is somewhat inaccurate considering the interstitial accumulation of amyloid and although cardiac amyloidosis traditionally has been regarded as a restrictive cardiomyopathy, the disease does not always completely fulfill the definition, which includes a restrictive ventricular filling, normal or reduced diastolic and systolic volumes, and normal wall thickness [84]. The echocardiographic definition for cardiac involvement in amyloidosis is defined as an interventricular septal thickness (IVST) >12 mm or a mean value of IVST and posterior wall thickness (PWT) of >12 mm, in absence of long standing hypertension or significant aortic valve disease. This definition is originally recommended for AL amyloidosis but is generally applied for ATTR amyloidosis as well [85, 86]. Role of echocardiography in identifying cardiac amyloidosis Early identification of cardiac amyloidosis is key for good clinical outcome. Echocardiography is one of the most widely used imaging techniques for cardiac evaluation, as it is readily available and often posing a first choice in investigating patients with symptoms of heart disease. In the diagnostic work-up of ATTR amyloidosis echocardiography serves as a base for establishing whether presence of cardiac infiltration exists. However, incidental left ventricular thickening is frequently encountered in echocardiographic examinations due to various aetiologies, and the main challenge is to elucidate when amyloid heart disease could be suspected. In patients with predominant cardiac amyloidotic phenotypes, neuropathy and other significative manifestations of amyloidosis usually are mild or absent. In such cases, echocardiography has the potential to raise early suspicion of amyloid heart disease or faulty direct attention towards an erroneous diagnostic route, placing the patient at risk for delayed diagnosis. In this view, the need for strong echocardiographic markers enabling better identification of cardiac amyloidosis is essential. Echocardiographic characteristics Echocardiographic characteristics in amyloid cardiomyopathy include symmetrically increased or slight septal dominant LV thickness, along with normal or slightly reduced cavity size. Increased thickness of the atrioventricular valves and thickened interatrial septum are other characteristic features [79, 87] (figure 4). The myocardium usually demonstrates a deviating pattern of echogenicity, initially described in the 1980s as a granular appearance or highly reflective echoes (HREs) [88, 89]. HREs have traditionally been viewed as a highly significant marker of infiltrative diseases, defined as persisting echoes at gain settings low enough to eliminate all parts of the surrounding myocardium [90]. However, the feature is limited to visual assessment of the echocardiogram and highly 9 dependent on the settings of the ultrasound machine. Pericardial effusion is another significant finding in cardiac amyloidosis, although unspecific as a separate finding and usually encountered only in advanced disease [91]. When present simultaneously, the above-mentioned features strongly suggest cardiac amyloidosis, Figure 4. Typical echocardiographic appearance in cardiac transthyretin amyloidosis. Upper left corner, parasternal long axis view; upper right corner, parasternal short axis showing the extent of ventricular thickening; lower left corner, apical four chamber view showing a thickened and hyperechogenic ventricular septum; lower right corner, subcostal view showing increased right ventricular free wall thickness and thickened atrial septum. Novel echocardiographic methods Various advanced echocardiographic techniques have been tested to enhance identification of cardiac amyloidosis, and among these, deformation analysis including strain and strain rate, is probably the most widely studied. Deformation analysis is derived either from tissue Doppler imaging or twodimensional (2D) speckle tracking technique. Speckle tracking detects the backscatter from reflected ultrasound, i.e., reflection from objects smaller 10 than the ultrasound wavelength, and allows tracking of these specific scatter patterns from frame to frame throughout the cardiac cycle. Deformation could be measured in three spatial directions: longitudinal, radial and circumferential. Strain is defined as the percentage of shortening or lengthening of a segment in relation to its original length and strain rate is merely the rate of deformation. By convention, myocardial shortening or thinning equals negative strain while lengthening and thickening corresponds to positive strain [92-94]. Hence, the definition of LV longitudinal end-systolic strain is expressed as percentage of shortening in end-systole in relation to the original length in end-diastole. Strain is a sensitive measure for detecting early abnormalities in systolic and diastolic function and has been shown to detect impairment before any visual signs of increased wall thickness were present in patients with ATTR amyloidosis [70]. The discriminative value of strain in cardiac amyloidosis is more uncertain since reduced deformation is usually encountered in thickened LV walls irrespective of the underlying aetiology [95, 96]. The most promising advanced echocardiographic marker is based on regional differences in LV strain from base to apex. When the global LV is assessed, cardiac amyloidosis patients of all three main subtypes frequently display lowest strain values in basal parts of the LV whereas apical strain remains relatively preserved, ie., apical sparing [65] (figure 5). Apical sparing has been reported to differentiate cardiac amyloidosis from other thick LV wall pathologies such as sarcomeric hypertrophic cardiomyopathy (HCM) - often having asymmetrical thickening and locally reduced strain, and aortic stenosis described as having a more patchy impairment of LV deformation [97]. Figure 5. Bull’s-eye plots from speckle tracking derived longitudinal strain measurements obtained in apical four-, three- and two-chamber views. To the left a patient with sarcomeric hypertrophic cardiomyopathy and to the right a patient with transthyretin amyloidosis and advanced cardiomyopathy. Note the generally reduced strain in the amyloidosis patient with preserved strain only in the apex (red colour). 11 Electrocardiography Electrocardiography (ECG) has a certain diagnostic value for identification of cardiac amyloidosis, especially when assessed in context with other diagnostic modalities. As a consequence of atrial amyloid deposition and accumulation in the conduction system, various degrees of atrioventricular blocks and atrial arrhythmias are frequently seen in cardiac amyloidosis [66, 67, 98]. Other typical findings include poor R-wave progression in chest leads, abnormal left axis deviation, and anterior and inferior pseudoinfarction patterns [73, 99]. As no actual myocyte hypertrophy is present in cardiac amyloidosis but rather distortion of normal myocyte architecture as a consequence of extensive amyloid deposits, signs of hypertrophy at the ECG are generally absent. Conversely, low voltage in chest and/or limb leads are readily displayed despite marked LV wall thickening, and it is considered a key diagnostic clue for infiltrative heart disease [100, 101]. Low voltage is most commonly defined as follows [102]: Amplitude of all limb leads <5 mm (0.5 mV) Amplitude of all precordial leads <10 mm (1.0 mV) The sum of the amplitude of the S wave in V1 + R wave in V5 or V6 <15 mm (1.5 mV) Low voltage accompanied with severely increased LV septal thickness (>20mm) is highly suggestive of cardiac amyloidosis with a reported sensitivity of 72% and specificity of 91% by Rahman et al. [103]. However, prevalence of low voltage varies greatly depending on the criterion used for definition and could roughly be estimated to be present in up to 50% in AL, ATTRwt and specific cardiac phenotypes of ATTRm [102, 104]. Notably, for the heterogeneous ATTRm disease, occurrence of low voltage is much lower for some genotypes [64, 99]. Carroll et al. demonstrated that QRS voltage divided by the cross-sectional area of the LV wall was lower in cardiac amyloidosis compared to aortic stenosis patients [101]. Other imaging modalities Bone scintigraphy using 99mTc-3.3-diphosphono-1.2-propanodicarboxylic acid (99mTc-DPD) is an imaging technique with particular diagnostic value that is currently recommended in patients where ATTR amyloidosis is suspected [105]. Both ATTRm and ATTRwt demonstrate strong cardiac uptake in 99mTc-DPD scintigraphy, whereas AL related cardiomyopathy at most show weak uptake, thus allowing differentiation between the subtypes [106, 107]. Furthermore, other hypertrophy associated cardiomyopathies such as hypertensive heart disease and HCM have absent cardiac uptake, which makes 99mTc-DPD a rather specific diagnostic technique for ATTR 12 amyloidosis [108]. However, identification of ATTR amyloidosis with the use of 99mTc-DPD scintigraphy is not complete as patients with type B fibrils appear to have absent uptake (Pilebro et al. In press). Other imaging techniques which probably are superior to echocardiography in identifying amyloid cardiomyopathy are cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET). Both techniques enables identification of cardiac amyloidosis and different reports have described the value of MRI for discriminating ATTR amyloidosis from other causes of increased LV wall thickness [91, 109, 110]. The major drawback of these imaging modalities is the limited accessibility as compared to echocardiography, the involvement of ionizing radiation in PET examinations and the high frequency of pacemaker carriers in the ATTR amyloidosis population which can be a contraindication to MRI. Differential diagnoses The “hypertrophic” appearance in cardiac amyloidosis renders the disease difficult to discriminate from other entities characterised by increased myocardial thickness. LV hypertrophy is most frequently induced as a physiological response to increased pressure-load, as seen in patients with longstanding hypertension and aortic stenosis [111]. Increased LV wall thickness could also occur due to intrinsic myopathic processes, only affecting the heart, such is the case in sarcomeric HCM, or occur secondary to a number of storage diseases [105]. Given this, ATTR cardiac amyloidosis is frequently subjected to misclassification and is probably an underdiagnosed disease. In fact, amyloid cardiomyopathy being preceded by an inaccurate HCM diagnosis is well reported [40, 64, 112]. Sarcomeric hypertrophic cardiomyopathy HCM is the most common genetic cardiac disorder, usually caused by mutations in genes encoding for proteins of the cardiac sarcomere. The disease can occur sporadically but is autosomal dominantly inherited in more than 50% of cases, with mutations detected in at least 11 different sarcomeric proteins [113, 114]. Predominant LV septal hypertrophy is present in more than two-thirds of HCM patients but any ventricular site could be involved, including symmetric and focal hypertrophy patterns, as well as increased RV free wall thickness. The grade of hypertrophy varies, and a maximal LV wall thickness >20 mm is not uncommon although even values above 50 mm have been reported, particularly in young patients [115117]. Histologically, HCM is characterised by hypertrophy of myocytes, myocyte disarray and interstitial fibrosis [118]. The myopathic process primarily causes diastolic dysfunction while systolic function is more preserved. A well described phenomenon associated with HCM is dynamic 13 LV outflow tract obstruction on the basis of systolic anterior motion of the mitral valve (SAM), usually seen in patients with extensive hypertrophy localised to the basal portion of the IVST [117]. This feature has been established as a differential trait between HCM and cardiac amyloidosis [119] although it occasionally occurs in the latter disease as well [120]. Other manifestations of HCM disease are atrial and ventricular arrhythmias, where the latter is responsible for sudden cardiac death predominantly occurring in young HCM patients [121]. Storage diseases A number of storage diseases infiltrates the heart, of which the most common apart from amyloidosis are sarcoidosis and hemochromatosis. Sarcoidosis primarily affects the lungs but concomitant cardiac involvement occurs in up to a third of the cases. The disease is characterised by granulomatous infiltration, which causes oedema associated ventricular thickening in early stages of the disease whereas development of fibrotic tissue in later stages causes segmental scar formation and dilation of the LV [122]. Hemochromatosis is an iron overload disease in which iron accumulation occurs within the cells and it mainly manifests as dilated cardiomyopathy with impaired systolic function [123]. Other infiltrative entities are metabolic disorders characterised by intracellular deposition such as Anderson-Fabry and Danon disease. Both these entities are systemic and associated with onset of disease manifestations in adolescence. Cardiac involvement in these two diseases includes symmetrically increased LV wall thickness. Although the prevalence of ‘hypertrophic’ cardiomyopathy increases with age in Anderson-Fabry disease, diagnosis is usually settled in an early age and none of these diseases have a high likelihood of being mixed up with amyloid cardiomyopathy [105, 124-126]. 14 Objectives The general aim of this thesis was twofold: (i) to enhance the ability to detect amyloid cardiomyopathy by the use of echocardiography and ECG and (ii) to examine the role of amyloid fibril composition and sex for cardiac involvement in ATTR patients. Specific aims: I. To identify the strongest features enabling differentiation between cardiac ATTR amyloidosis and HCM using echocardiography and ECG. II. To examine the frequency and extent of right ventricular involvement in different phenotypes of ATTR amyloidosis and compare the findings with HCM. III. To assess the dispersion of fibril composition in ATTR amyloidosis patients and to analyse the impact of fibril type, age and sex on ventricular thickness. IV. To investigate whether fibril composition has impact on the outcome of ATTR amyloidosis patients after LT, in regard to cardiac function. 15 Materials and methods Study population The ATTR patients included in this thesis were evaluated at Umeå University hospital and diagnosis was settled by histopathological analysis of tissue biopsy specimens, showing positive Congo red staining. All but two patients had genetically verified TTR mutations in DNA sequencing analysis, the remaining two patients were diagnosed as ATTRwt amyloidosis, both presenting positive 99mTc-DPD-scintigraphies and negative genetic testing for TTR mutations. Studies were carried out in a retrospect fashion by analysis of digitally saved echocardiographic examinations conducted at time for or close to diagnostic work-up, unless stated otherwise. Studies III and IV only included patients in whom fibril composition had been analysed (typing of fibrils has been performed in Swedish ATTR patients since 2005). All ATTR amyloidosis patients included in the four substudies are illustrated in the Venn diagram below (figure 6). Study I (n=33) 3 Study II (n=61) 4 47 13 1 1 Study III (n=107) 2 9 1 7 23 5 6 Study IV (n=24) Figure 6. Hereditary transthyretin amyloidosis patients included in studies I-IV. Study I The study comprised 35 patients with cardiac ATTR amyloidosis, all fulfilling the echocardiographic definition for cardiac involvement [86]. Thirty-seven patients with diagnosed HCM were included to enable a comparison of ATTR cardiac amyloidosis with another thick wall pathology. Nine patients were excluded from the study due to atrial fibrillation (n=2), poor image quality (n=4) and previously undergone septal ablation (n=2) or myectomy (n=1). 16 Thus, the final study population comprised 33 ATTR amyloidosis patients, median age 65 (63–74) years and 30 patients with HCM, median age 56 (41– 64) years. Two patients carried the TTR H88A mutation and the remaining 31 carried the TTR V30M mutation. Patients with HCM were diagnosed by a clinical cardiologist at Umeå University Hospital having specific knowledge and experience in HCM disease and in concordance with current guidelines, namely presence of increased left ventricular thickness (any segment >15 mm) in absence of long-standing systemic hypertension, aortic stenosis and other diseases able to cause the same extent of ventricular hypertrophy. Eight HCM patients had undergone genetic testing and sarcomeric mutations were confirmed in four of these patients. In order to evaluate the results in study I, a small set of 8 patients constituting a validation group, median age 72 (60-78) years, were added to the study. All included in this small study group were ATTR amyloidosis patients, referred primarily due to clinical signs of heart failure. They all underwent echocardiographic evaluation in which increased LV myocardial thickness was revealed. TTR gene mutations were as follows: V30M (n=3), H88A (n=1), V122I (n=1), G54L (n=1) and two patients proved to have ATTRwt amyloidosis. Study II Sixty-five patients with ATTR amyloidosis were admitted to the study. Four ATTR patients were excluded due to atrial fibrillation (n=3) and moderate size atrial septal defect (n=1) resulting in a total of 61 ATTR patients in the study, median age 64 (57-72) years. The majority of ATTR patients carried the TTR V30M mutation (n=58). Other genotypes were TTR G54L (n=1), T60A (n=1), and the A45S (n=1) mutations. Patients with ATTR amyloidosis were categorised into two subgroups according to the echocardiographic definition of cardiac involvement – one group with IVST ≤ 12 mm (noncardiac ATTR) and one IVST >12 mm (cardiac ATTR). In addition, 25 HCM patients were included, median age 54 (41-66) years, all having an endomyocardial biopsy proven disease or verified mutations in sarcomere encoding genes. HCM patients had a ventricular myocardial thickness >15 mm, all with maximal thickness in the septal portion of the LV. Thirty healthy controls, median age 61 (51-69) years, comprising a subset of individuals originally recruited to the Umeå General Population Heart Study [127], who underwent echocardiographic examination in 2006 were also added to study II. None of the controls had any cardiovascular or systemic disease and did not use any medications known to interfere with cardiac function. 17 Study III ATTR V30M amyloidosis patients that had their fibril composition determined along with digitally recorded echocardiographic examinations were subject to inclusion in study III. In all, 107 ATTR amyloidosis patients, median age 64 (52-71) years, were eligible for the study. Thirteen patients were excluded from the echocardiographic part of the study due to previous cardiac surgery (n=5), status post myocardial infarction (n=1), severe aortic stenosis (n=1), pacemaker rhythm (n=4) or atrial fibrillation (n=2). Study IV Twenty-four ATTR amyloidosis patients that had their fibril type determined as either type A or type B and had undergone LT constituted the study population. For inclusion, echocardiographic studies needed to be accessible prior to LT and at least one year post LT. Ten patients proved to have type A TTR fibrils and 14 patients had type B fibrils. Patients with type A fibrils had a mean age of 64±7 years and were transplanted 4.7±3.3 years after onset of disease. Patients with type B fibrils had a mean age of 56±14 years and were transplanted 3.3±1.3 years after onset of disease. All but two patients were positive for the TTR V30M mutation; these two patients proved to have the A45S and the L55G mutations, respectively. Methodology Echocardiography Patients with ATTR amyloidosis and HCM underwent a comprehensive echocardiographic examination including image acquisition from parasternal, apical and subcostal views. Echocardiographic studies in patients and controls were carried out using Vivid 7 (studies I-IV) and Vivid E9 (GE Healthcare, Horten, Norway) (studies I-III) and Philips IE 33 (Philips ultrasound, Bothell, WA) (study II). Image acquisition was performed mainly by three experienced investigators, according to the guidelines described in American Society of echocardiography (ASE) [128, 129]. Offline analysis was performed using commercially available software packages - Echopac PC General Electric, version 8.0.1 to 113 (studies I-IV), (Horten, Norway) and TomTec Image Arena version 4.5 (Unterschleissheim, Germany) (study II). Offline measurements were analysed in accordance with ASE guidelines [129-131]. 18 Two dimensional and M-mode echocardiography From parasternal long axis views, either in M-mode or 2D recordings, measurements of LV end-diastolic (LVDD) and systolic (LVSD) diameter were carried out (studies II-IV) as well as end-diastolic measurements of IVST and PWT (studies I-IV). To assess the extent of increased LV thickness, Spirito-Maron index was calculated in study I by adding the maximum thickness of each LV segment (septal, posterior, lateral and anterior) from basal and midventricular short axis view [132]. From apical four- and two-chamber views left atrial (LA) end-systolic volumes (LAVI), LV end-diastolic (EDVI) and end-systolic (ESVI) volumes were measured and indexed to body surface area (BSA). In studies I, III and IV, LVEF was calculated using the Simpson biplane model. In study II, RV end-diastolic diameter (RVEDD) was measured at the basal region and right atrial (RA) area was measured in end-systole. Tricuspid longitudinal systolic displacement (TAPSE) was assessed from M-mode recordings at the base of RV free wall by measuring the amplitude between the start of the Q-wave in the ECG and the end of the T-wave. A value <17 mm indicated impaired longitudinal RV systolic function. RV free wall thickness (RVT) was measured in subcostal view in end diastole and a value >5 mm was considered abnormal [133]. In study III, LV mass (LVMI) was calculated according to the modified formula of Devereux [134] and indexed to height [135]. Doppler echocardiography For assessment of LV diastolic function, early (E) to late (A) diastolic velocities ratio (E/A), deceleration time (DT) and isovolumic relaxation time (IVRT) were measured from pulsed wave Doppler recordings with sample volume placed at the mitral tips. From pulsed wave tissue Doppler recordings at the basal lateral segment of the LV, peak early diastolic velocity (e’ or Em) was obtained and E/e’ was calculated (studies I-IV). SV and cardiac output (CO) were measured from pulsed Doppler recordings with sample volume placed in the LV outflow tract (studies I and IV) and were indexed to BSA in study III (stroke index, SI; cardiac index, CI). In study I, peak systolic velocities across the aortic valve (AoVmax) were measured from continuous Doppler flow recordings. Deformation analysis Deformation analysis was derived from speckle tracking technique in apical four- (studies II and IV) and two-chamber views (studies I and III). For assessment of LV longitudinal end-systolic strain in Echopac the LV wall was manually delineated. Care was taken to place the region of interest in the endocardial and myocardial segments, avoiding the blood pool and pericardial areas (figure 7). The package software automatically defined the 19 endocardial border in subsequent frames and the LV wall was divided into six regional segments in each view. Tracking quality was checked and corrected by manual adjustments if any region was deemed to track inadequately. Only segments with sufficient tracking were included in the analysis. Values from the regional segments were averaged to generate global longitudinal strain (studies I, III) and peak systolic, early diastolic and late diastolic strain rate (study IV). End-systolic strain was defined using aortic valve closure from pulsed wave Doppler recordings of the LV outflow tract. A minimum of 5 out of 6 approved segments was needed for global strain analysis. Figure 7. Left ventricular segmental and global strain derived from speckle tracking technique in apical four-chamber view. In study I, LV strain values from the apical four-chamber view were averaged over basal, mid respectively apical segments in order to evaluate apex-to-base gradient patterns. The formula proposed by Phelan et al. was applied but modified as to only include values from apical four-chamber view [97]: Relative apical strain = average apical strain average basal strain + average mid strain In study II, TomTec Image arena was utilised for strain analysis as the echocardiographic examinations were obtained from different ultrasound vendors. TomTec Arena allows analysis of standard Digital Imaging and Communications in Medicine (DICOM) images irrespective of the ultrasound platform utilized for image acquisition. A similar approach as 20 described above was applied with the only difference that solely the endocardium was outlined, in both LV and RV separately, thus generating longitudinal endocardial strain (figure 8). Peak RV free wall, peak global (RV free wall + septal wall) as well as peak regional systolic strain were calculated. In addition, RV strain values were averaged for basal, mid and apical levels in order to evaluate apex-to-base gradients as described for study I. Figure 8. Endocardial tracing of the global right ventricular wall and the corresponding six segmental peak longitudinal strain curves: green, basal free wall; grey, mid free wall; turquoise, apical free wall; blue, apical septum; yellow, mid septum; pink; basal septum; black curve, global strain. Myocardial tissue characterisation Study I: In order to quantitatively assess the deviating echogenic pattern in the LV wall in patients with ATTR amyloidosis, an in-house custom developed research software was employed for tissue texture analysis using B-mode apical four-chamber views (Department of Biomedical Engineering – R&D, Umeå University Hospital, Umeå, Sweden). First, a region of interest was placed in the darkest area of the image (blood pool) where the intensity was set to zero and in the brightest area (pericardium) where intensity was set to 190. The IVST was then manually outlined and cropped before grayscale median (GSM) and entropy were calculated. GSM is defined as the normalised reflectivity of the tissue and entropy is a measure of the heterogeneity of the reflection within the tissue. Heterogeneous graytone composition is equal to high entropy values while more homogeneous tissue generates low entropy [136]. 21 Electrocardiography Study I: Standard 12 lead electrocardiograms (50 mm/s) obtained in neartime to the echocardiographic examinations were analysed. Measurements of QRS duration and PQ interval was performed and presence of severe conduction delay was noted. Assessment of QRS voltage was made according to the Sokolow-Lyon criterion – the amplitude of R-wave in V1 + S-wave in V5 or V6, whichever was the largest [137]. QRS voltage was measured in millimetres (mm) on the ECG recordings, where 10 mm corresponded to 1 mV. Low voltage was defined as a QRS voltage amplitude <15 mm (1.5 mV) [101]. Statistics Continuous data were expressed as medians (interquartile range) in studies I-III and as means (SD) in study IV. Categorical variables were expressed as counts (percentages) (studies I-IV). Pairwise comparisons for count data were carried out using non-parametric Mann Whitney U test and Fisher’s exact test for dichotomous data. Simple linear regression was used in study III in order to assess the association between IVST and age. Multiple regression analysis was conducted in study III to evaluate the contribution of fibril type, age, sex, disease duration and hypertension on IVST. As IVST was slightly skewed, the variable was transformed to the natural logarithm (ln) for regression analysis. Statistical analyses were performed using IBM SPPS statistics version 18-22 (studies I-IV), R (R version 3.0.2, 2013-09-25) and package rpart (version 4.1-5) (study I). Classification trees Study I: The method of Classification and Regression trees was applied in order to categorise the patient sample into subgroups, ie., either classify patients as HCM or as ATTR, by using a set of candidate variables obtained from ECG and echocardiography [138]. The ability for each variable to separately differentiate ATTR from HCM was first established by examining receiver-operating characteristics (ROC) curves and calculating the area under the curve (AUC). AUC enabled ranking of variables, according to the ability to classify patients into correct groups. The threshold allowing best classification was calculated from each ROC curve using Youden’s J Statistic [139]. Sensitivity (proportion of correctly classified ATTR patients) and specificity (proportion of correctly classified HCM patients) were calculated for the estimated thresholds. Thereafter we wanted to combine a set of variables and thereby create a diagnostic model likely to have stronger differential performance than by only using a single variable. The classification tree basically is a multivariate non-parametric method allowing separation of subjects into distinct 22 subgroups in sequential levels or splits. First the univariate variables were ranked and the parameter that best separated patients into correct subgroups with the corresponding cut-off were selected. For each new level, the algorithm was applied to a decreased number of patients rather than the entire sample. The model continues partitioning of the data until no further split is possible or in pre-defined number of steps. Validation of how well the calculated thresholds from the classification trees would perform on new clinical data were carried out in two ways. First leave-one-out cross validation was applied during the creation of the trees, and second the final classification trees were retested with the validation group. Creation of classification trees were performed on the basis of: (i) only conventional echocardiographic variables available in clinical practice and (ii) all investigated variables from echocardiography and ECG, including both previously suggested amyloid markers and more technically advanced variables. Gini index was used for calculation of optimal cut-points. Reproducibility Study I: Intra- and interobserver reproducibility were tested in 10 subjects that were randomly selected from the study population. Interobserver variability was assessed by two experienced investigators who were unaware of each other’s measurements. Coefficient of variation was calculated as the standard deviation of differences between the two sets of variables divided by the overall mean. Ethics All parts of studies I-IV have been approved by the local ethical review board in Umeå, Sweden and studies were conducted in accordance with the Declaration of Helsinki. The studies on ATTR amyloidosis patients were included as part of a larger study (06-084M) and echocardiographic analysis on patients with HCM in studies I and II also had approval (08-101M). 23 Results and Discussion Despite being a well described part of the ATTR amyloidotic disease, amyloid cardiomyopathy generally is perceived as a rare exception among clinicians. However, the prevalence of amyloid cardiomyopathy is probably underestimated, partly due to the lack of strong echocardiographic markers separating the entity from other thick wall pathologies. Furthermore, the role of fibril composition in development of cardiac amyloidosis is somewhat unclear. This thesis proposes a method for easier identification of cardiac amyloidosis, investigates the severity of cardiac involvement, and hopefully shed some light on the phenotypic variation in Swedish ATTR amyloidosis patients. Differentiating ATTR amyloidosis from HCM As previously mentioned, a number of markers derived from either echocardiography or ECG have been proposed for identification of cardiac amyloidosis but it should be noted that the vast majority primarily have been tested in AL amyloidosis cohorts. In studies I and II, ATTR patients with echocardiographic signs of cardiac infiltration were compared to patients with HCM. ATTR amyloidosis patients were significantly older than HCM (median age 65 vs. 56 years, p<0.001) and had higher median heart rate (72 vs. 60 bpm, p<0.001) but thinner IVST (median 16 vs. 18 mm, p=0.044). All variables from ECG and echocardiography that were included in the analyses in study I are presented in table 1, together with their univariate ability to separate ATTR amyloidosis from HCM. Among the tested variables, QRSvoltage, entropy and heart rate were the independent measures that displayed strongest differential traits. While low QRS voltage has been described as a hallmark for cardiac amyloidosis, this was not the case for the ATTR population in the present study. Our findings rather suggest that absence of increased QRS voltage is characteristic for ATTR amyloidosis. This finding is concordant with descriptions of ATTR T60A [52]. Since granular appearance or HREs in the LV wall is such a wellestablished feature of cardiac amyloidosis we sought to elucidate whether this could be quantified. One such measure was entropy, displaying a more homogenic grayscale pattern of the septal wall in ATTR patients than in HCM. However, investigating myocardial texture in aim to identify cardiac amyloidosis is not novel, entropy for instance has previously been reported to differ cardiac amyloidosis from healthy controls [136]. As for heart rate being different between the two patient groups, this probably is explained by presence of autonomic neuropathy in ATTR amyloidosis which is associated with an increase in heart rate [140, 141] in 24 combination with a proportionally higher use of beta-blockers in HCM patients (63% vs 18%, p<0.001). Table 1. Univariate classification statistics including all variables tested for classification in study 1. Variable AUC threshold sensitivity specificity cv.err E/A ratio 0.729 (4) 0.96 0.724 0.697 0.295 IVSt/PWt 0.714 (6) 1.63 0.533 0.939 0.254 AoVmax, m/s 0.711 (7) 1.81 0.500 0.909 0.286 IVSt, mm 0.647 (9) 17.50 0.533 0.788 0.333 ECHO LAVI, ml/m2 0.645 (10) 30.69 0.759 0.545 0.355 PWt, mm 0.637 (11) 10.50 0.500 0.727 0.619 IVRT, ms 0.618 (12) 104.00 0.931 0.333 0.607 SpiritoMaron index 0.610 (13) 45.75 0.889 0.400 0.404 LV EDVI, ml/m2 0.608 (14) 47.19 0.793 0.485 0.371 DT, ms 0.556 (18) 276.50 1.000 0.200 0.600 E/e’ 0.548 (19) 6.28 0.280 0.931 0.660 0.515 (20) 12.82 0.207 0.909 0.468 QRS voltage, mm 0.860 (1) 23 0.815 0.778 0.222 HR, bpm 0.758 (3) 71 0.933 0.515 0.714 PQ interval, ms 0.708 (8) 187 0.793 0.630 0.694 QRS duration, ms 0.569 (17) 87 0.966 0.222 0.449 Entropy 0.760 (2) 2.90 0.759 0.697 0.279 Relative apical strain 0.729 (5) 0.88 0.69 0.8 0.764 GSM 0.600 (15) 60.57 0.897 0.333 0.410 Strain Rate, 1/s, % 0.573 (16) -0.895 0.840 0.424 0.415 Septal strain, % 0.502 (21) -14.16 0.483 0.636 0.492 Global LV strain,% 0.485 (22) -14.66 0.633 0.455 0.540 LV ESVI ml/m2 ECG Deformation and texture AUC, estimated area under curve; cv.err, cross-validation error; E/A, early to late diastolic transmitral velocities ratio; IVSt/PWt, interventricular septal to posterior wall thickness ratio; AoVmax, peak aortic Doppler flow velocity; LAVI, left atrial volume index; IVRT, isovolumic relaxation time; LV, left ventricular; EDVI, enddiastolic ventricular volume index; DT, deceleration time; E/e’, early mitral diastolic inflow to early diastolic tissue Doppler velocity ratio; ESVI, end-systolic ventricular volume index; HR, heart rate; GSM, gray-scale median. Variables are sorted by the AUC within each category of variables with overall AUC ranking noted in parentheses next to the AUC. 25 In study II, RV structure and function were assessed and compared between 42 cardiac ATTR patients and 25 patients with HCM. Cardiac ATTR patients were older than those with HCM (median age 69 vs. 54 years, p<0.0001) and had lower median weight (70 vs. 85 kg, p=0.028). Assessment of LV wall dimensions showed thicker IVST (median 18 vs. 16 mm, p=0.017) but thinner PWT (median 10 vs. 12 mm, p =0.004) in HCM patients compared to cardiac ATTR patients, and thus more asymmetrical wall thickening in HCM (IVST/PWT, median 1.8 vs. 1.4, p<0.0001). The results showed that neither traditional echocardiographic measures such as RVEDD, RA area and TAPSE nor global RV strain could separate the two diseases. Global RV longitudinal strain was equally impaired in both cardiac ATTR and HCM patients and were significantly lower with respect to healthy controls (p=0.005 and p=0.0014, respectively). Interestingly, when regional strain was investigated, differences in apex-to-base gradients emerged where cardiac ATTR patients displayed reduced RV strain in basal segments (median -14.9 vs. -27.5 %, p=0.016) while apical strain was reduced in HCM patients (median -17.5 vs. -27.3 %, p=0.014) (figure 9). Consequently, an RV apical sparing pattern seems to be present in cardiac ATTR patients, which is similar to the apical sparing of longitudinal strain previously reported for the LV [97, 142, 143]. To the best of our knowledge, this pattern has not been described previously for the RV in ATTR patients. A plausible explanation for this discrepancy between ATTR and HCM patients might be sought in the distinct myopathic processes of the two diseases. As basal portions of the LV are the initially affected segments in ATTR amyloidosis it is likely that amyloid deposits are larger in basal segments of the RV as well [68, 69]. This could be a direct consequence of coronary artery supply, reaching basal portions prior to apical ones. Conversely, impaired apical strain in HCM patients might be attributed to potential subclinical involvement of the apex, as no HCM patient had apical hypertrophy. 26 Figure 9. Peak systolic longitudinal strain measured in basal, mid and apical regions of the right ventricle in patients with cardiac and non-cardiac transthyretin amyloidosis (ATTR), hypertrophic cardiomyopathy (HCM), and healthy controls. Classification tree In study I, two classification models were created, one unimodal - only including basic echocardiographic variables commonly used in everyday practice, and one multimodal - including all variables obtained from both echocardiography and ECG. The strongest classification model in terms of highest accuracy and lowest classification error was the multimodal tree, consisting of two levels based on QRS voltage and the degree of symmetry of LV wall thickness. Intriguingly, the results revealed that the easy accessible variables derived from echocardiography and ECG were superior to the more advanced techniques in discriminating ATTR from HCM. A QRS voltage ≥30 mm classified patients as HCM, this level only included HCM patients. The remainder, that is, patients qualifying for QRS voltage <30 mm were subsequently separated using IVST/PWT where a value ≥1.6 supported the diagnosis of HCM and a value <1.6 was consistent with ATTR (figure 10). The combination of QRS voltage and IVST/PWT in the classification tree enabled higher sensitivity (0.939) and specificity (0.833) than any univariate feature assessed in this study. 27 The main purpose of this classification tree is not to establish a definite diagnosis. For that, 99mTc-DPD scintigraphy might pose a next step in the clinical investigation and histopathological verification from tissue biopsies along with genetic testing remain gold standards [61, 105]. Nevertheless, this proposed classification tree poses a clue for amyloid heart disease in a group of patients with increased LV wall thickness and can distinguish patients in need for a more throughout diagnostic work-up. As the first level only contained HCM patients, it indicates that ATTR amyloidosis is unlikely if QRS voltage exceeds 30 mm. Furthermore, when the classification tree was validated by the small cohort of ATTRm and ATTRwt patients, all patients were correctly classified. Absence of increased QRS amplitudes and close to symmetrical LV thickness have been reported previously as hints for cardiac amyloidosis [40] and the voltage to mass ratio proposed by Carroll et al. is based on a relatively similar concept [101]. However, the diagnostic cut-offs provided in the present study are novel and as the measures of IVST and PWT are performed readily in clinical practice the present classification tree enables an easy and quick recognition of ATTR cardiac amyloidosis. Figure 10. Classification tree for differentiation of patients with cardiac transthyretin amyloidosis (ATTR) from patients with hypertrophic cardiomyopathy (HCM). IVSt/PWt, interventricular septal thickness/posterior wall thickness. The numbers under each category represent the number of ATTR/HCM patients reclassified in that category. Sensitivity =0.939, specificity=0.833, cross validation error=0.127. 28 Reproducibility Inter- and intraobserver reproducibility were calculated for IVST, PWT, E/A and QRS voltage in study I. The coefficient of variation was acceptable to high for both intra- and interobserver measurements. Intra-observer reproducibility was 10% for IVST, 15% for PWT, 5% for E/A and 4% for QRS voltage. The interobserver reproducibility was 10% for IVST, 14% for PWT, 7% for E/A ratio and 6% for QRS voltage. Right heart involvement in ATTR amyloidosis In order to achieve a better understanding of the extent of RV involvement in ATTR amyloidosis patients, we set out to investigate this in study II both in cardiac ATTR patients (IVST>12 mm) and non-cardiac ATTR patients (IVST≤12 mm). Right heart involvement in the Swedish ATTR amyloidosis cohort was relatively common in patients with concomitant LV wall thickening. Among cardiac ATTR patients, 57% had increased RVT whereas only one patient in the non-cardiac ATTR group had increased RVT. A substantial portion of cardiac ATTR patients presented with preserved longitudinal systolic function as assessed by TAPSE, where impairment was noticed only for 24%. When RV-function was assessed in an AL amyloidosis cohort, impairment of systolic function was reported despite normal LV wall thickness [81]. This was not the case for the non-cardiac ATTR amyloidosis patients in the present study, since they did not differ from healthy controls either in geometry or function, displaying comparable TAPSE and global and segmental RV strain values. As AL amyloidosis is a more rapidly progressing disease, these findings are not surprising. The majority of non-cardiac ATTR patients in study II were relatively young, mainly having early onset of disease, and the major cardiac manifestations previously described in earlyonset patients are those of autonomic neuropathy and conduction disturbances [29, 43]. Cardiac involvement according to fibril composition A number of studies on smaller samples of ATTR amyloidosis patients have revealed a rather intriguing pattern, where type A fibril patients appear to be both older, having late-onset of disease and more frequently display amyloid cardiomyopathy, as compared to type B patients. In study III, we set out to study this in a larger cohort, including all patients from the Swedish cluster which had had their fibril composition settled. The results showed that type A patients displayed significantly increased IVST (median 17 vs. 11 mm, p<0.0001), PWT (median 12 vs. 10 mm, p<0.0001) (figure 11) and lower LV 29 global strain (-15.8 vs. -19.1 %, p=0.005), in comparison to patients with type B TTR fibrils, which is consistent with previous findings [44]. Among patients with type A fibrils, the vast majority had increased LV myocardial thickness, as IVST >12 mm was seen in 97% of males and 73% of females. Notably, LVEF was preserved in virtually all of these patients whereas LV longitudinal strain was frequently impaired. The prevalence of increased LV wall thickness in type B patients was lower but not absent, as nearly half (42%) of males and 25 % of women had an IVST>12 mm. Figure 11. Comparison between transthyretin amyloidosis patients with type A and type B fibrils where each measured point represents an individual patient for: a. Interventricular septal thickness (IVST) and b. Posterior wall thickness (PWT). Significantly increased IVST and PWT are displayed in patients with type A fibrils. Dispersion of fibril composition among V30M patients Virtually all ATTR patients with type A fibrils in study III were older than 50 years of age. Conversely, type B patients mainly had early-onset of disease, although a subset of patients had onset after the age of 60. Knowing that ATTRwt amyloidosis has a predilection for elderly males and so far has only been associated with type A TTR fibrils [37], it is tempting to speculate whether men to a greater extent than women with ATTRm have type A TTR fibrils. Our results in study III showed no significant difference in dispersion of fibril types between the sexes although the distribution was not completely even: Male to female ratio for type A fibrils 36:13 and for type B 36:22. Thus, previously described sex-related differences in development of amyloid heart disease could not be attributed solely to fibril composition. 30 Determinants of increased LV wall thickness In an attempt to establish the main determinants for increased LV wall thickness in ATTR patients a multivariate regression model was created including fibril composition, sex, age, disease duration and presence of hypertension as predictors and ln IVST as response variable. The results revealed that age, fibril type and sex all had a positive effect on ln IVST, whereas neither disease duration nor hypertension showed any significant impact (table 2). Furthermore, simple linear regression revealed that ln IVST was positively associated with age in both males (R2 = 0.563, p<0.0001) and females (R2 = 0.364, p=0.005) with type B fibrils, whereas no such correlation was present in type A fibril patients. This might indicate that some progression of amyloid cardiac infiltration occurs in type B patients as well, although at a slower rate than in type A patients. It could be argued that cleavage of the intact type B TTR might occur along with ageing, converting type B fibrils into type A fibrils. However, type B fibrils have been detected in patients with disease duration of more than 15 years, indicating that protein cleavage does not occur in all patients with time [144]. Table 2. Multiple regression analysis for factors associated with the natural logarithm of left ventricular septal thickness (dependent variable) in study III. Regression coefficient B Standardized Std. Error Beta p value (Constant) 1,817 0.098 Fibril type 0.203 0.044 0.369 <0.0001 Sex 0.202 0.040 0.350 <0.0001 Hypertension 0.073 0.041 0.132 0.077 Age (years) 0.008 0.002 0.424 <0.0001 Disease duration 0.008 0.005 0.109 0.113 1 31 <0.0001 Sex-related differences in cardiac involvement Study III: The most common initial symptom in both men and women was neuropathy, present in 86% of males and 97% of women. Cardiac manifestations was the initial symptom solely in 7% of the ATTR patients, and only in males. Disease duration was significantly longer in women compared to men (p=0.016) (table 3). When sex-related echocardiographic differences were investigated in patients with type A fibrils, evidence for more severe cardiac involvement in males emerged. This was shown by increased LV wall thickness (IVST, p=0.007; PWT, p=0.010), higher LVMI (p=0.008) and lower LV septal strain (p=0.037) in males as compared to females. Conversely, these differences were not apparent between men and women with type B fibrils (table 4). These findings are intriguing and provide a potential explanation to the more favourable outcome in late-onset women post LT, with respect to late-onset males [49]. Rapezzi et al. also reported a lower degree of cardiac involvement in women compared to males, but in their study, this difference vanished in women of post-menopausal age [45]. In study III, type A women, all between 56-86 years of age generally had some degree of cardiac involvement but in contrast to the findings of Rapezzi et al. these patients still displayed less cardiac involvement than type A males. It should be noted that cardiac dimensions differ between men and women, being lower in the latter [145]. Correcting for these differences are partly but not completely overcome by indexing for body size, using height or BSA [129]. In addition to thinner LV walls and lower LVMI, type A women also displayed more preserved systolic strain. Interestingly, Tasaki et al. investigated the proportion of wild-type and variant TTR in cardiac tissue and demonstrated that the amount of wild-type TTR increased with age, predominantly in males, whereas the total amount of amyloid decreased in women but increased in males [146]. This indicates that differences in incorporation of amyloid deposits into the interstitial space is a more likely explanation to the sex-related discrepancies than general physiological differences between men and women. 32 Table 3. Clinical characteristics with respect to sex for transthyretin V30M amyloidosis patients included in study III. Men (n=72) Women (n=35) 36/36 13/22 0.223 Type A 68 (52-79) 74 (56-86) 0.079 Type B 54 (31-76) 59 (30-79) 0.197 2 (1-18) 4 (1-22) 0.016 62 (86) 33 (97) 0.214 GI symptoms 5 (7) 2 (6) 1.000 Cardiac manifestations 5 (7) 0 (0) 0.170 Ocular manifestations 1 (1) 0 (0) 1.000 Type A 1 (3) 1 (8) 0.443 Type B 5 (14) 7 (32) 0.102 Cardiac comorbidities, n (%) 6 (8) 1 (3) 0.423 Pacemaker, n (%) 5 (7) 3 (9) 0.715 Type A 18 (50) 8 (61) 0.475 Type B 11 (31) 12 (55) 0.070 Type A/Type B, n p value Age at exam, median years (range) Disease duration, median years (range) Initial symptoms, n (%) Neuropathy Liver transplanted, n (%) Hypertension, n (%) 1 Type A, mixture of intact and fragmented transthyretin; Type B, only full length transthyretin; GI, Gastro-intestinal. Continuous data are presented as median (range) and categorical data are presented as counts and percentages. Statistically significant differences are marked in bold. 33 Table 4. Echocardiographic findings in transthyretin V30M amyloidosis patients with type A and type B fibrils with respect to sex, in study III. Amyloid fibril Type A Type B composition Men (n=30) Women (n=11) p value Men (n=33) Women (n=20) p value 74 (64-82) 70 (66-80) 0.437 78 (65-88) 76 (65-87) 0.699 5 (17) 2 (18) 0.100 0 (0) 1 (5) 0.365 29 (97) 8 (73) 0.052 14 (42) 5 (25) 0.247 IVST, mm 18 (15-20) 14 (12-16) 0.007 12 (10-15) 11 (10-13) 0.243 PWT, mm 12 (11-13) 10 (9-10) 0.010 10 (8-11) 9 (8-10) 0.054 LVDD, mm 49 (42-52) 47 (39-50) 0.329 48 (46-51) 47 (44-50) 0.467 LVSD, mm 29 (24-34) 28 (25-31) 0.657 29 (25-34) 28 (24-31) 0.424 LVMI, g/m 166 (135-209) 114 (108-152) 0.008 118 (90-130) 97 (81-121) 0.248 LAVI, ml/m2 33.0 (23.0-42.8) 27.8 (21.5-41.6) 0.528 24.1 (20.1-33.4) 21.8 (18.6-33.7) 0.678 LVEF, % 64 (58-69) 65 (58-74) 0.676 63 (58-71) 66 (57-71) 0.585 Heart rate, bpm Pericardial effusion, n (%) Dimensions IVST >12 mm, n (%) Doppler measurements E/A 0.8 (0.7-1.0) 0.9 (0.8-1.2) 0.346 1.1 (0.9-1.4) 0.9 (0.7-1.2) 0.126 E/em 10.0 (8.0-13.6) 9.3 (7.6-14.4) 0.957 6.4 (5.2-9.8) 8.6 (6.0-11.9) 0.030 IVRT, ms 94 (76-114) 95 (90-124) 0.788 80 (63-92) 83 (67-90) 0.545 SV, ml 78 (70-89) 73 (58-92) 0.546 76 (65-90) 72 (62-84) 0.202 SI, ml/m2 41 (37-45) 43 (35-55) 0.643 36 (34-47) 43 (36-49) 0.233 CO, l/min 5.9 (5.1-6.4) 5.5 (4.1-6.1) 0.192 5.7 (5.2-6.8) 5.2 (4.7-6.0) 0.022 CI, l/min/m2 3.1 (2.6-3.4) 3.2 (2.5-3.8) 0.797 2.9 (2.7-3.3) 3.1 (2.6-3.5) 0.707 -7.8 (-4.5- -11.8) -11.9 (-8.8- -14.8) 0.037 -15.3 (-12.0- -17.6) -16.4 (-13.3- -18.8) 0.270 -15.4 (-14.2- -17.7) -18.0 (-15.6- -19.7) 0.057 -19.1 (-17.4- -20.1) -19.1 (-15.8- -21.0) 0.924 Speckle tracking derived longitudinal strain Septal basal strain, % LV global strain, % 1 Data are presented as medians (interquartile range), unless stated otherwise. Type A, amyloid fibril composed of a mixture of full length and fragmented transthyretin; Type B, full length transthyretin only; IVST, interventricular septal thickness; PWT, posterior wall thickness; LVDD, left ventricular diastolic diameter; LVSD, left ventricular systolic diameter; LVMI, Left ventricular mass index; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; E/A, early/late mitral diastolic filling velocity; E/em, early mitral diastolic filling/early myocardial diastolic filling velocity; IVRT, Isovolumic relaxation time; SV, stroke volume; SI, stroke index; CO, cardiac output; CI, cardiac index. Statistically significant differences are marked in bold. 34 Fibril composition transplantation determines outcome after liver Study IV: Reports of the relatively poor outcome in late-onset ATTR patients after LT in combination with descriptions of the different phenotypes attributable to fibril composition led to the hypothesis that type A patients might be at risk for development of post-transplant cardiomyopathy. In type A patients, echocardiographic examinations were carried out prior to (mean 8 (2-16) months) and after LT (mean, 27 (16-54) months). For type B patients the corresponding time points were pre LT: mean 8 (314) months and post LT: mean 26 (16-43) months, the duration did not significantly differ between type A and type B patients. In the baseline echocardiographic examination (pre LT), type A fibril patients tended to have a higher grade of cardiac involvement, at least as shown by higher values of PWT (12±2 vs. 10±3 mm, p=0.027). But other than that, no significant differences were seen between type A and type B patients pre LT. Observation periods were similar as well - type A patients, 4 (2-8) years; type B patients, 5.5 (3-8) years. From pre to post LT examinations, patients with type A fibrils exhibited a significant worsening in LV structure and function showing marked increased IVST (15±3 to 18±5 mm, p=0.010) and PWT (12±2 to 14±2 mm, p=0.017), increased left atrial volumes (48±25 to 64±23 ml, p=0.009) and deteriorated diastolic functional parameters (E/A, 1.2±0.8 to 1.7±1.2, p=0.015; E/e’, 10.9±2.8 to 18.6±11.1, p=0.043) indicating increased filling pressures. In addition, systolic functional parameters in terms of LVEF and systolic strain rate decreased (64±6 to 53±7 %, p=0.005 and -0.88±0.19 to -0.64±0.16 s-1, p=0.015, respectively) (figure 12). By contrast, in type B patients significant differences between pre- and post-transplant were neither noticed for myocardial thickness nor systolic and diastolic function. This study offers a potential explanation to the rapid cardiac deterioration occurring in a subset of ATTR patients after LT. Biochemical studies have noted higher exchange of TTR amyloid deposits in type A patients than in type B, where essentially all mutated TTR had vanished within two years in type A as compared to 70-80% in type B patients [144]. The preponderance to incorporate wild type TTR into amyloid deposits after LT seems to be a determinant factor for aggravated cardiomyopathy. Ihse and colleagues demonstrated that amyloid deposits progressively were substituted with wild type TTR foremost in type A patients, and this could possibly explain the higher propensity for development of amyloid cardiomyopathy in those patients [144]. Fibril composition analyses in other genotypes than TTR V30M are limited but in those reported, type A fibrils seem to dominate [38]. In study IV, two patients died a couple of years after LT, both these patients 35 had non-V30M genotypes. Other studies investigating two ATTR A60T and six H88A patients - both mutations associated with amyloid cardiomyopathy, found type A fibrils in all [39, 147]. Figure 12. Individual values of a. left ventricular ejection fraction and b. global left ventricular systolic strain rate pre and post liver transplantation (tx) in transthyretin amyloidosis patients, categorised according to fibril composition. Filled lines represent type A patients and dashed lines type B patients. Liver transplantation as a treatment option In ATTR patients, short duration of disease in combination with good nutritional status are the major determinants for favourable outcome of LT while late-onset disease and presence of severe cardiomyopathy are contraindications for the procedure [49]. The increased prevalence of cardiac complications post LT in type A patients, which was not found in the same extent in type B patients, makes it a questionable treatment option in patients with type A fibrils. In light of this, fibril composition might be a more suitable selection criterion than an age limit. Furthermore, whereas late-onset male patients have as poor survival after LT as non-transplanted patients this is not the case for female patients [49] in whom survival is more comparable to early-onset patients. The found differences in cardiac involvement between type A males and type A females in study III indicates that females, despite having a more malign fibril composition display less extensive LV wall thickening and more preserved systolic function. A highly interesting objective would therefore be to examine whether female type A patients might favour from LT irrespective of age at onset. The patient 36 sample in study IV was too small to enable evaluation of sex-related differences after LT, and therefore it is beyond the scope of this thesis. Methodological considerations This thesis incorporates a broad range of echocardiographic measures, used both to establish extent of amyloidotic heart disease and as diagnostic markers. While some of these parameters are used clinically in everyday practise others are mainly applied in research areas, and the role of a couple of these measures deserves to be more thoroughly discussed. LVEF has been the method of choice for evaluation of systolic function in daily practice and in scientific studies. In study III, systolic differences in LV myocardial function between males and females were detected with deformation analysis whereas LVEF was preserved in all four patient groups. This is not surprising since the method has limited reproducibility and lacks the sensitivity to detect subtle changes in systolic function. Conversely, LV global longitudinal strain has repeatedly shown superior sensitivity in detecting early abnormalities in systolic cardiac function and in addition, is a highly feasible method [148, 149]. Global LV strain might therefore be a more suitable echocardiographic technique to evaluate progression of LV disease over time. The main disadvantage for speckle tracking based deformation analysis is that vendors provide different algorithms for analysis. However, a recent investigation stated that the variability in global LV strain between the major ultrasound software vendors on the market were comparable with or superior to LVEF and other commonly used echocardiographic parameters [150]. Deformation analysis in the RV is more complicated, partly because the thin RV wall is more difficult to trace but also because fewer studies have been performed on RV strain and normative values are based on small study samples with relatively high variability between studies [131]. In study II, a wide interquartile range was noted especially for RV segmental strain. A higher difficulty in accurately tracing the thin RV wall compared to the LV is a potential explanation for that, in combination with various degrees of myopathic involvement of the RV free wall in the study subjects. At present, this limits the clinical use of RV strain and the discriminative pattern described between ATTR and HCM patients could merely be regarded as a potential diagnostic clue in this exploratory study. Its clinical relevance remains to be elucidated in future studies. 37 Limitations This thesis is based on cross-sectional or short follow-up studies conducted in retrospect. These types of studies are associated with a number of limitations, of which the most important is that only one time-point has been investigated (studies I-III). The chosen time-point was set to be as close as possible to time for diagnosis thus representing rather early phases in the disease process, although in a few patients echocardiographic examinations were only available several years after diagnosis. Other time-points potentially could have generated different results. Another limitation is that the retrospect approach to some extent limits the accessibility of data, not always allowing optimised echocardiographic examinations for the study purpose. When differences between ATTR cardiomyopathy and other causes of hypertrophy were investigated, HCM was the only thick wall pathology used for comparisons which might limit the generalisation of the results. The reason for only including HCM patients in the comparison group was because these patients had been thoroughly investigated to ensure an accurate HCM diagnosis. Hypertensive heart disease is more commonly encountered in the clinical population but it is an entity with higher risk of including other diagnoses than those intended. The patients in this thesis were solely from the Swedish ATTR amyloidosis cohort, thus mainly involving the TTR V30M genotype presenting with a mixed phenotype. The present findings may therefore not be directly applicable to other cohorts with different genotypes. Nevertheless, the proposed classification method in study I successfully classified patients both with ATTRwt and non-V30M disease when the validation group were tested. Lastly, disease duration was estimated anamnestically, but patients with predominant cardiac phenotype, mainly seen among type A patients, probably have had a longer disease duration than that perceived from onset of symptoms. Therefore, a bias towards underestimated disease duration in type A patients is possibly present. 38 Conclusions Differentiation of ATTR cardiomyopathy from HCM is aided by using simple and easy accessible variables from ECG and echocardiography, available in daily clinical practise. The classification tree, based on a combination of QRS voltage (<30 mm) and IVST/PWT (<1.6 mm) aids in determining in which patients ATTR cardiac amyloidosis should be suspected. RV involvement is frequently displayed in ATTR patients with concomitant LV wall thickening while patients with non-cardiac ATTR have similar geometry and function as healthy controls. The RV deformation gradient from base to apex reveals an apical sparing pattern not previously described for the RV in ATTR patients, which was not present in patients with HCM. Potential clinical significance of this finding remains to be studied further. Strong determinants for development of amyloid cardiomyopathy in Swedish ATTR V30M patients are: Male sex Ageing Type A fibrils ATTR V30M cardiomyopathy is prevalent in both women and men with type A fibrils, but the extent of cardiac involvement is more profound in the latter group than the former. This might explain the better outcome after LT in late-onset women. Patients with type A fibrils rapidly deteriorate in their cardiac function after LT, while type B patients’ cardiac function remains more preserved post-transplant. It could therefore be questioned whether LT is a suitable treatment option for type A patients. 39 Acknowledgements My greatest gratitude goes to my supervisor and friend Per Lindqvist for giving me the opportunity to begin this partly tough but mostly exciting research journey, for your never-ending encouragement and belief in me, for giving me the freedom to plan my own projects, and yet always being available for support. Ole Suhr, co-supervisor, for sharing your massive knowledge in amyloid heart disease. Urban Wiklund, co-supervisor, for lots of helpful advice throughout these years, both regarding statistics and research in general. To all my co-authors, especially Gabriel Granåsen for teaching me statistics when we were working on study I, and for your patience when explaining it to me several times. Christer Grönlund for helping me with the tissue characterisation analysis and for being a good travel companion in Athens. To Björn Pilebro for your interesting thoughts about amyloidosis and for sharing your clinical knowledge. Michael Henein for being encouraging, helpful and for quick response. Stellan Mörner for sharing your knowledge about HCM disease. Kerstin Rosenqvist and Eva Karlsson for solving all sorts of administrative problems and always having answers to my questions. To my roommate Roffa, for lots of helpful advice regarding research. To Hans-Erik and others working in the FAP-team, for being positive and always helpful. Thanks also to those involved in amyloidosis research, Urban, Malin, Nina, Jonas, and Intissar for being fun travel companions in Brazil. To Eva Karlendal and Kalle Forsberg for your flexibility with me being away from clinic during these years and to all colleagues in Clinical physiology. A special thanks to Christer Backman for sharing a lot of your knowledge in amyloid heart disease and echocardiography. To Jenny, Simon and Manne for sharing my interest in downhill skiing and mud 40 running. Camilla for always being a supportive friend in- and outside of work. Tack till mina föräldrar, Gunilla och Jan-Olof, och mina syskon Erik, Håkan och Maria för allmänt stöd i livet och för välbehövliga pauser i Kittjavan. Till min man Peder, för ovillkorligt stöd trots ibland långa avstånd mellan oss, och för att du hjälpt mig hålla fokus denna höst under skrivandet av denna avhandling. Ett stort tack till alla patienter som ingår i den här avhandlingen och de jag fått träffa vid hjärteko-undersökningarna, jag har lärt mig massor om amyloidos genom att få träffa er personligen. 41 References 1. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005; 1753: 11-22. 2. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004; 255: 159-178. 3. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014; 21: 221-224. 4. Mucchiano G, Cornwell GG, 3rd, Westermark P. Senile aortic amyloid. Evidence for two distinct forms of localized deposits. Am J Pathol. 1992; 140: 871-877. 5. Pepys MB. Amyloidosis. Annu Rev Med. 2006; 57: 223-241. 6. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996; 77: 313-315. 7. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007; 36: 411-423. 8. Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett. 2001; 498: 201-203. 9. Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014; 5: 45-54. 10. Westermark GT, Westermark P. Transthyretin and amyloid in the islets of Langerhans in type-2 diabetes. Exp Diabetes Res. 2008; 2008: 429274. 11. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem. 2001; 276: 27207-27213. 12. Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013; 52: 19131926. 42 13. Squier TC. Oxidative stress and protein aggregation during biological aging. Exp Gerontol. 2001; 36: 1539-1550. 14. De Navasquez S, Forbes JR, Holling HE. Right Ventricular Hypertrophy of Unknown Origin: So-Called Pulmonary Hypertension. Br Heart J. 1940; 2: 177-188. 15. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952; 75: 408-427. 16. Araki S, Ando Y. Transthyretin-related familial amyloidotic polyneuropathyProgress in Kumamoto, Japan (1967-2010). Proc Jpn Acad Ser B Phys Biol Sci. 2010; 86: 694-706. 17. Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl. 1976; 590: 1-64. 18. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011; 10: 1086-1097. 19. Heldestad V, Nordh E. Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy. Muscle Nerve. 2007; 35: 189195. 20. Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis common complications of a rare disease. Orphanet J Rare Dis. 2014; 9: 61. 21. Hornsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation. 2004; 78: 112-116. 22. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002; 59: 1771-1776. 23. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013; 29: 63-76. 43 24. Ikeda S, Hanyu N, Hongo M, Yoshioka J, Oguchi H, Yanagisawa N, et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain. 1987; 110 ( Pt 2): 315-337. 25. Bittencourt PL, Couto CA, Clemente C, Farias AQ, Palacios SA, Mies S, et al. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol. 2005; 12: 289-293. 26. Olsson M, Jonasson J, Cederquist K, Suhr OB. Frequency of the transthyretin Val30Met mutation in the northern Swedish population. Amyloid. 2014; 21: 18-20. 27. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994; 235: 479-485. 28. Suhr OB, Lindqvist P, Olofsson BO, Waldenstrom A, Backman C. Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid. 2006; 13: 154-159. 29. Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid. 2010; 17: 63-68. 30. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, PlanteBordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008; 15: 181-186. 31. Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet. 2003; 40: e120. 32. Westermark P, Sletten K, Johansson B, Cornwell GG, 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990; 87: 2843-2845. 33. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chainassociated amyloidosis. Arch Intern Med. 2005; 165: 1425-1429. 34. Pitkanen P, Westermark P, Cornwell GG, 3rd. Senile systemic amyloidosis. Am J Pathol. 1984; 117: 391-399. 44 35. Cornwell GG, 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983; 75: 618-623. 36. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008; 40: 232-239. 37. Bergstrom J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005; 206: 224-232. 38. Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013; 20: 142-150. 39. Hellman U, Lundgren HE, Westermark P, Stafberg C, Nahi H, Tachlinski S, et al. A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family. Eur J Med Genet. 2015; 58: 211-215. 40. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013; 34: 520-528. 41. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012; 164: 222-228 e221. 42. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid. 2005; 12: 127-130. 43. Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology. 2004; 63: 129-138. 44. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008; 216: 253-261. 45 45. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, et al. Genderrelated risk of myocardial involvement in systemic amyloidosis. Amyloid. 2008; 15: 40-48. 46. Goncalves I, Alves CH, Quintela T, Baltazar G, Socorro S, Saraiva MJ, et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem. 2008; 317: 137-142. 47. Jonsen E, Suhr OB, Tashima K, Athlin E. Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life. Amyloid. 2001; 8: 52-57. 48. Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid. 2005; 12: 233-238. 49. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl. 2009; 15: 1229-1235. 50. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, et al. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation. 2015; 99: 1847-1854. 51. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation. 2002; 73: 745-751. 52. Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012; 33: 1120-1127. 53. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998; 66: 229-233. 54. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007; 7: 235-242. 46 55. Okamoto S, Zhao Y, Lindqvist P, Backman C, Ericzon BG, Wijayatunga P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid. 2011; 18: 200-205. 56. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981; 63: 1285-1288. 57. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112: 2047-2060. 58. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993; 104: 618-620. 59. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, PlanteBordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012; 79: 785792. 60. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310: 2658-2667. 61. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8: 31. 62. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369: 819-829. 63. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015. 64. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009; 120: 1203-1212. 65. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014; 129: 1840-1849. 66. Eriksson A, Eriksson P, Olofsson BO, Thornell LE. The cardiac atrioventricular conduction system in familial amyloidosis with 47 polyneuropathy. A clinico-pathologic study of six cases from Northern Sweden. Acta Pathol Microbiol Immunol Scand A. 1983; 91: 343-349. 67. Eriksson A, Eriksson P, Olofsson BO, Thornell LE. The sinoatrial node in familial amyloidosis with polyneuropathy. A clinico-pathological study of nine cases from northern Sweden. Virchows Arch A Pathol Anat Histopathol. 1984; 402: 239-246. 68. Porciani MC, Lilli A, Perfetto F, Cappelli F, Massimiliano Rao C, Del Pace S, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009; 16: 63-70. 69. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003; 107: 2446-2452. 70. Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenstrom A. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr. 2006; 7: 22-30. 71. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36: 2585-2594. 72. Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990; 16: 1135-1141. 73. Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol. 1983; 52: 137-146. 74. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997; 337: 898-909. 75. Di Bella G, Minutoli F, Piaggi P, Casale M, Mazzeo A, Zito C, et al. Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation. Am J Cardiol. 2015; 116: 11221127. 76. Plehn JF, Friedman BJ. Diastolic dysfunction in amyloid heart disease: restrictive cardiomyopathy or not? J Am Coll Cardiol. 1989; 13: 54-56. 48 77. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001; 104: 1594-1597. 78. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004; 94: 10081010. 79. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997; 78: 74-82. 80. Cappelli F, Porciani MC, Bergesio F, Perlini S, Attana P, Moggi Pignone A, et al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2012; 13: 416-422. 81. Bellavia D, Pellikka PA, Dispenzieri A, Scott CG, Al-Zahrani GB, Grogan M, et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging. 2012; 13: 680-689. 82. Cappelli F, Baldasseroni S, Bergesio F, Perlini S, Salinaro F, Padeletti L, et al. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis. Clin Cardiol. 2015; 38: 69-75. 83. Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005; 91: 250-256. 84. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29: 270-276. 85. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012; 126: 1286-1300. 86. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79: 319-328. 49 87. Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO. Noninvasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J. 1984; 52: 321-326. 88. Backman C, Olofsson BO. Echocardiographic features in familial amyloidosis with polyneuropathy. Acta Med Scand. 1983; 214: 273-278. 89. Chiaramida SA, Goldman MA, Zema MJ, Pizzarello RA, Goldberg HM. Realtime cross-sectional echocardiographic diagnosis of infiltrative cardiomyopathy due to amyloid. J Clin Ultrasound. 1980; 8: 58-62. 90. Eriksson P, Eriksson A, Backman C, Hofer PA, Olofsson BO. Highly refractile myocardial echoes in familial amyloidosis with polyneuropathy. A correlative echocardiographic and histopathological study. Acta Med Scand. 1985; 217: 27-32. 91. Takeda M, Amano Y, Tachi M, Tani H, Mizuno K, Kumita S. MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease. Jpn J Radiol. 2013; 31: 693-700. 92. Teske AJ, De Boeck BW, Melman PG, Sieswerda GT, Doevendans PA, Cramer MJ. Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking. Cardiovasc Ultrasound. 2007; 5: 27. 93. Blessberger H, Binder T. NON-invasive imaging: Two dimensional speckle tracking echocardiography: basic principles. Heart. 2010; 96: 716-722. 94. Mondillo S, Galderisi M, Mele D, Cameli M, Lomoriello VS, Zaca V, et al. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med. 2011; 30: 71-83. 95. Beladan CC, Popescu BA, Calin A, Rosca M, Matei F, Gurzun MM, et al. Correlation between global longitudinal strain and QRS voltage on electrocardiogram in patients with left ventricular hypertrophy. Echocardiography. 2014; 31: 325-334. 96. Serri K, Reant P, Lafitte M, Berhouet M, Le Bouffos V, Roudaut R, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006; 47: 1175-1181. 50 97. Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012; 98: 1442-1448. 98. Eriksson P, Karp K, Bjerle P, Olofsson BO. Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy. Br Heart J. 1984; 51: 658-662. 99. Hongo M, Yamamoto H, Kohda T, Takeda M, Kinoshita O, Uchikawa S, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol. 2000; 85: 849-853. 100. Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J. 1992; 13: 623-627. 101. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982; 49: 9-13. 102. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014; 114: 1089-1093. 103. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004; 43: 410-415. 104. Dungu J, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012; 164: 72-79. 105. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35: 2733-2779. 106. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2propanodicarboxylic acid scintigraphy in the aetiological diagnosis of 51 amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011; 38: 470478. 107. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. J Am Coll Cardiol Img. 2011; 4: 659-670. 108. Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012; 5: 755-758. 109. Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015; 8: 50-59. 110. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014; 7: 157-165. 111. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart. 2003; 89: 1104-1109. 112. Morner S, Hellman U, Suhr OB, Kazzam E, Waldenstrom A. Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med. 2005; 258: 225-230. 113. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001; 33: 655-670. 114. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012; 60: 705-715. 115. Rosca M, Calin A, Beladan CC, Enache R, Mateescu AD, Gurzun MM, et al. Right Ventricular Remodeling, Its Correlates, and Its Clinical Impact in Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2015; 28: 13291338. 116. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009; 54: 220-228. 117. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic 52 observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995; 26: 1699-1708. 118. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000; 84: 476-482. 119. Eriksson P, Backman C, Eriksson A, Eriksson S, Karp K, Olofsson BO. Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography. Acta Med Scand. 1987; 221: 39-46. 120. Philippakis AA, Falk RH. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide. Circulation. 2012; 125: 1821-1824. 121. Williams LK, Frenneaux MP, Steeds RP. Echocardiography in hypertrophic cardiomyopathy diagnosis, prognosis, and role in management. Eur J Echocardiogr. 2009; 10: iii9-14. 122. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978; 58: 1204-1211. 123. Gulati V, Harikrishnan P, Palaniswamy C, Aronow WS, Jain D, Frishman WH. Cardiac involvement in hemochromatosis. Cardiol Rev. 2014; 22: 5668. 124. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004; 34: 236-242. 125. Sugie K, Yamamoto A, Murayama K, Oh SJ, Takahashi M, Mora M, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology. 2002; 58: 1773-1778. 126. Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol. 2002; 13 Suppl 2: S147-149. 127. Lindqvist P, Waldenstrom A, Henein M, Morner S, Kazzam E. Regional and global right ventricular function in healthy individuals aged 20-90 years: a pulsed Doppler tissue imaging study: Umea General Population Heart Study. Echocardiography. 2005; 22: 305-314. 53 128. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002; 15: 167-184. 129. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18: 14401463. 130. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009; 22: 107-133. 131. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23: 685-713; quiz 786-688. 132. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1990; 15: 808-813. 133. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1-39 e14. 134. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450-458. 135. Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc Ultrasound. 2005; 3: 17. 136. Pinamonti B, Picano E, Ferdeghini EM, Lattanzi F, Slavich G, Landini L, et al. Quantitative texture analysis in two-dimensional echocardiography: 54 application to the diagnosis of myocardial amyloidosis. J Am Coll Cardiol. 1989; 14: 666-671. 137. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949; 37: 161-186. 138. Breiman L. Classification and Regression Trees: Wadsworth & Brooks/Cole Advanced Books & Software; 1984. 139. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3: 32-35. 140. Klein CM. Evaluation and management of autonomic nervous system disorders. Semin Neurol. 2008; 28: 195-204. 141. Ando Y, Suhr OB. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid. 1998; 5: 288-300. 142. Lee GY, Kim HK, Choi JO, Chang SA, Oh JK, Jeon ES, et al. Visual Assessment of Relative Apical Sparing Pattern Is More Useful Than Quantitative Assessment for Diagnosing Cardiac Amyloidosis in Borderline or Mildly Increased Left Ventricular Wall Thickness. Circ J. 2015; 79: 15751584. 143. Bostan C, Sinan UY, Canbolat P, Kucukoglu S. Cardiac amyloidosis cases with relative apical sparing of longitudinal strain. Echocardiography. 2014; 31: 241-244. 144. Ihse E, Suhr OB, Hellman U, Westermark P. Variation in amount of wildtype transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl). 2011; 89: 171-180. 145. Svedenhag J, Larsson TP, Lindqvist P, Olsson A, Rythen Alder E. Individual reference values for 2D echocardiographic measurements. The Stockholm Umea Study. Clin Physiol Funct Imaging. 2014. 146. Tasaki M, Ueda M, Obayashi K, Koike H, Kitagawa K, Ogi Y, et al. Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach. Int J Cardiol. 2013; 170: 69-74. 147. Ihse E, Stangou AJ, Heaton ND, O'Grady J, Ybo A, Hellman U, et al. Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: an analysis on transplanted transthyretin T60A amyloidosis patients. Biochem Biophys Res Commun. 2009; 379: 846-850. 55 148. Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012; 60: 1067-1076. 149. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009; 2: 356-364. 150. Farsalinos KE, Daraban AM, Unlu S, Thomas JD, Badano LP, Voigt JU. Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors: The EACVI/ASE Inter-Vendor Comparison Study. J Am Soc Echocardiogr. 2015; 28: 1171-1181 e1172. 56
